LEGISLATURE OF NEBRASKA

ONE HUNDRED EIGHTH LEGISLATURE

FIRST SESSION

LEGISLATIVE BILL 22

Introduced by Wayne, 13.

Read first time January 05, 2023

Committee:

- 1 A BILL FOR AN ACT relating to marijuana; to amend sections 2-505, 2-506, 2 2-509, 28-417, 28-419, 28-439, 77-4301, 77-4302, 77-4303, 77-4304, 3 77-4305, 77-4306, 77-4309, 77-4310.01, and 77-4310.03, Reissue 4 Revised Statutes of Nebraska, and sections 28-401, 28-405, 28-416, 28-1354, and 28-1701, Revised Statutes Cumulative Supplement, 2022; 5 6 to decriminalize use and possession of marijuana; to remove 7 marijuana from the marijuana and controlled substances tax; to 8 rename a fund; to eliminate obsolete provisions; to harmonize 9 provisions; to repeal the original sections; and to outright repeal sections 2-5701, 28-463, 28-464, 28-465, 28-466, 28-467, 28-468, and 10 28-469, Reissue Revised Statutes of Nebraska. 11
- 12 Be it enacted by the people of the State of Nebraska,

1 Section 1. Section 2-505, Reissue Revised Statutes of Nebraska, is

- 2 amended to read:
- 3 2-505 (1) Hemp may only be cultivated by a USDA-licensed hemp
- 4 producer or a person meeting the requirements of section 2-5701 or in
- 5 compliance with this section.
- 6 (2) Before a person may be licensed to cultivate hemp under the
- 7 Nebraska Hemp Farming Act, such person shall submit an application on a
- 8 form prescribed by the department that includes, but is not limited to,
- 9 the following:
- 10 (a) If the applicant is an individual, the applicant's full name,
- 11 birthdate, mailing address, telephone number, and valid email address;
- 12 (b) If the applicant is an entity and not an individual, (i) the
- 13 name of the applicant, mailing address, telephone number, and valid email
- 14 address, (ii) the full name of each officer, director, partner, member,
- 15 or owner owning in excess of ten percent of equity or stock in such
- 16 entity, (iii) the full name of each key participant as defined in 7
- 17 C.F.R. 990.1, and (iv) the birthdate, title, mailing address, telephone
- 18 number, and valid email address of each such person or key participant;
- (c) The proposed acreage to be cultivated or the square footage of a
- 20 greenhouse or other indoor space to be cultivated;
- 21 (d) The street address, legal description, location ID, and GPS
- 22 coordinates for each field, greenhouse, building, or other site where
- 23 hemp will be cultivated. The site information may be verified by the
- 24 department; and
- 25 (e) Maps depicting each site where hemp will be cultivated, with
- 26 appropriate indications for entrances, field boundaries, and specific
- 27 locations corresponding to the GPS coordinates provided under subdivision
- 28 (d) of this subsection.
- 29 (3) Before a person may be licensed to cultivate hemp under the
- 30 Nebraska Hemp Farming Act, such person shall submit with the application
- 31 a nonrefundable application fee as set by the department pursuant to

11

12

sites.

- 1 section 2-508.
- (4) Before a person may be licensed to cultivate hemp under the 2 3 Nebraska Hemp Farming Act, such person shall submit a site registration 4 fee as set by the department pursuant to section 2-508. The site registration fee shall be paid for each separate site where the applicant 5 will cultivate hemp. Subsequent modifications to the sites listed in the 6 application shall be submitted on forms prescribed by the department 7 along with a site modification fee and shall only take effect upon 8 9 written approval of the department. The applicant must certify that all sites where hemp is to be cultivated are under the control of the 10

applicant and that the department shall have unlimited access to all such

- (5) After the department receives approval by the United States

 Secretary of Agriculture for the state plan described in section 2-516,

 an initial cultivator license application may be submitted at any time,

 except that the department may set a cutoff date for applications ahead

 of the growing season. An initial cultivator license issued by the

 department expires on December 31 in the calendar year for which it was

 issued.
- 20 (6) A renewal application for a license to cultivate hemp shall be submitted on forms prescribed by the department. A renewal application is due by December 31 and shall be accompanied by the cultivator license fee and the site registration fee for all sites listed in the renewal application. The renewal cultivator license is valid from January 1 or when the license is granted, whichever is later, through December 31 next following.
- (7) A cultivator license shall lapse automatically upon a change of ownership or location, and a new license must be obtained. The licensee shall promptly provide notice of change in ownership or location to the department.
- 31 (8) An application and supporting documents submitted to the

- 1 department under this section are not public records subject to
- 2 disclosure pursuant to sections 84-712 to 84-712.09. Such information may
- 3 be submitted to the United States Department of Agriculture pursuant to
- 4 the requirements of the federal Agriculture Improvement Act of 2018 or
- 5 any other federal statute, rule, or regulation, and may be submitted to
- 6 law enforcement.
- 7 Sec. 2. Section 2-506, Reissue Revised Statutes of Nebraska, is
- 8 amended to read:
- 9 2-506 (1) Except for handling by an approved testing facility, a
- 10 USDA-licensed hemp producer, or a cultivator licensed under section
- 11 2-505, a person shall not process, handle, or broker hemp plants or plant
- 12 parts in this state unless the person meets the requirements of section
- 13 2-5701 or is in compliance with this section and licensed as a processor-
- 14 handler or broker under the Nebraska Hemp Farming Act.
- 15 (2) Before a person may be licensed to process, handle, or broker
- 16 hemp in this state, such person shall submit an application on a form
- 17 prescribed by the department that includes, but is not limited to, the
- 18 following:
- 19 (a) If the applicant is an individual, the applicant's full name,
- 20 birthdate, mailing address, telephone number, and valid email address;
- 21 (b) If the applicant is an entity and not an individual, the name of
- 22 the applicant, mailing address, telephone number, and valid email
- 23 address, the full name of each officer and director, partner, member, or
- 24 owner owning in excess of ten percent of equity or stock in such entity,
- 25 and the birthdate, title, mailing address, telephone number, and valid
- 26 email address of each such person;
- 27 (c) The street address, legal description, location ID, and GPS
- 28 coordinates for the site where hemp will be processed or handled, if
- 29 applicable; and
- 30 (d) Maps depicting the site where hemp will be processed or handled,
- 31 if applicable, with appropriate indications for entrances and specific

1 locations corresponding to the GPS coordinates provided under subdivision

- 2 (c) of this subsection.
- 3 (3) Before a person may be licensed to process, handle, or broker
- 4 hemp, such person shall submit with the application a nonrefundable
- 5 application fee as set by the department pursuant to section 2-508.
- 6 (4) Before a person may be licensed to process or handle hemp, such
- 7 person shall submit a site registration fee as set by the department
- 8 pursuant to section 2-508. The site registration fee shall be paid for
- 9 each separate site where hemp is processed or handled. Subsequent
- 10 modifications to the sites listed in the application shall be submitted
- on forms prescribed by the department along with the site modification
- 12 fee and shall only take effect upon written approval of the department.
- 13 The applicant must certify that all sites where hemp is to be processed
- 14 or handled are under the control of the applicant and that the department
- shall have unlimited access to all such sites.
- 16 (5) An initial processor-handler or broker license application may
- 17 be submitted at any time. An initial processor-handler or broker license
- 18 issued by the department expires on December 31 in the calendar year for
- 19 which it was issued.
- 20 (6) A renewal application for a processor-handler or broker license
- 21 shall be submitted on forms prescribed by the department. A renewal
- 22 application is due by December 31 and shall be accompanied by the
- 23 processor-handler or broker license fee and, if applicable, the site
- 24 registration fee for all sites listed in the renewal application. The
- 25 renewal processor-handler or broker license is valid from January 1 or
- 26 when the license is granted, whichever is later, through December 31 next
- 27 following.
- 28 (7) A processor-handler or broker license shall lapse automatically
- 29 upon a change of ownership or location, and a new license must be
- 30 obtained. The licensee shall promptly provide notice of change in
- 31 ownership or location to the department.

1 (8) A processor-handler licensee who also brokers hemp shall not be 2 required to also obtain a broker license under this section.

- (9) An application and supporting documents submitted to the department under this section are not public records subject to disclosure pursuant to sections 84-712 to 84-712.09. Such information may be submitted to the United States Department of Agriculture pursuant to the requirements of the federal Agriculture Improvement Act of 2018 or any other federal statute, rule, or regulation, and may be submitted to law enforcement.
- Sec. 3. Section 2-509, Reissue Revised Statutes of Nebraska, is amended to read:
- 2-509 The Nebraska Hemp Program Fund is established. The fund shall 12 13 be administered by the department for the purpose of covering the costs of the department in administering sections 2-504 to 2-516 and 2-5701. 14 The fund may receive appropriations by the Legislature, gifts, grants, 15 16 federal funds, and any other funds both public and private. All fees 17 collected by the department under section sections 2-508 and 2-5701 shall be remitted to the State Treasurer for credit to the fund. Transfers from 18 19 the Nebraska Hemp Program Fund to the Noxious Weed Cash Fund may be made as provided in section 2-958. Transfers from the Nebraska Hemp Program 20 Fund to the Fertilizers and Soil Conditioners Administrative Fund may be 21 22 made as provided in section 81-2,162.27. Any money in the fund available for investment shall be invested by the state investment officer pursuant 23 24 to the Nebraska Capital Expansion Act and the Nebraska State Funds 25 Investment Act.
- Sec. 4. Section 28-401, Revised Statutes Cumulative Supplement, 27 2022, is amended to read:
- 28 28-401 As used in the Uniform Controlled Substances Act, unless the context otherwise requires:
- 30 (1) Administer means to directly apply a controlled substance by 31 injection, inhalation, ingestion, or any other means to the body of a

- patient or research subject;
- 2 (2) Agent means an authorized person who acts on behalf of or at the
- 3 direction of another person but does not include a common or contract
- 4 carrier, public warehouse keeper, or employee of a carrier or warehouse
- 5 keeper;
- 6 (3) Administration means the Drug Enforcement Administration of the
- 7 United States Department of Justice;
- 8 (4) Controlled substance means a drug, biological, substance, or
- 9 immediate precursor in Schedules I through V of section 28-405.
- 10 Controlled substance does not include distilled spirits, wine, malt
- 11 beverages, tobacco, hemp, or any nonnarcotic substance if such substance
- 12 may, under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 301 et
- 13 seq., as such act existed on January 1, 2014, and the law of this state,
- 14 be lawfully sold over the counter without a prescription;
- 15 (5) Counterfeit substance means a controlled substance which, or the
- 16 container or labeling of which, without authorization, bears the
- 17 trademark, trade name, or other identifying mark, imprint, number, or
- 18 device, or any likeness thereof, of a manufacturer, distributor, or
- 19 dispenser other than the person or persons who in fact manufactured,
- 20 distributed, or dispensed such substance and which thereby falsely
- 21 purports or is represented to be the product of, or to have been
- 22 distributed by, such other manufacturer, distributor, or dispenser;
- 23 (6) Department means the Department of Health and Human Services;
- 24 (7) Division of Drug Control means the personnel of the Nebraska
- 25 State Patrol who are assigned to enforce the Uniform Controlled
- 26 Substances Act;
- 27 (8) Dispense means to deliver a controlled substance to an ultimate
- 28 user or a research subject pursuant to a medical order issued by a
- 29 practitioner authorized to prescribe, including the packaging, labeling,
- 30 or compounding necessary to prepare the controlled substance for such
- 31 delivery;

1 (9) Distribute means to deliver other than by administering or 2 dispensing a controlled substance;

- 3 (10) Prescribe means to issue a medical order;
- 4 (11) Drug means (a) articles recognized in the official United
- 5 States Pharmacopoeia, official Homeopathic Pharmacopoeia of the United
- 6 States, official National Formulary, or any supplement to any of them,
- 7 (b) substances intended for use in the diagnosis, cure, mitigation,
- 8 treatment, or prevention of disease in human beings or animals, and (c)
- 9 substances intended for use as a component of any article specified in
- 10 subdivision (a) or (b) of this subdivision, but does not include devices
- or their components, parts, or accessories;
- 12 (12) Deliver or delivery means the actual, constructive, or
- 13 attempted transfer from one person to another of a controlled substance,
- 14 whether or not there is an agency relationship;
- 15 (13) Hemp has the same meaning as in section 2-503;
- 16 (14)(a) Marijuana means all parts of the plant of the genus
- 17 cannabis, whether growing or not, the seeds thereof, and every compound,
- 18 manufacture, salt, derivative, mixture, or preparation of such plant or
- 19 its seeds, including, but not limited to, tetrahydrocannabinols extracted
- 20 or isolated from the plant or any product or preparation containing such
- 21 <u>tetrahydrocannabinols</u>, <u>including</u>, <u>but not limited to</u>, <u>edible products</u>,
- 22 <u>tinctures</u>, and ointments.
- 23 (b) Marijuana does not include the mature stalks of such plant,
- 24 hashish, tetrahydrocannabinols extracted or isolated from the plant,
- 25 fiber produced from such stalks, oil or cake made from the seeds of such
- 26 plant, any other compound, manufacture, salt, derivative, mixture, or
- 27 preparation of such mature stalks, the sterilized seed of such plant
- 28 which is incapable of germination, or cannabidiol contained in a drug
- 29 product approved by the federal Food and Drug Administration.
- 30 (c) Marijuana does not include hemp<u>or resins extracted from hemp in</u>
- 31 the possession of a person as authorized under the Nebraska Hemp Farming

1 <u>Act</u>.

- 2 (d) When the weight of marijuana is referred to in the Uniform
- 3 Controlled Substances Act, it means its weight at or about the time it is
- 4 seized or otherwise comes into the possession of law enforcement
- 5 authorities, whether cured or uncured at that time: \pm
- 6 (e) When industrial hemp as defined in section 2-5701 is in the
- 7 possession of a person as authorized under section 2-5701, it is not
- 8 considered marijuana for purposes of the Uniform Controlled Substances
- 9 Act;
- 10 (15) Manufacture means the production, preparation, propagation,
- 11 conversion, or processing of a controlled substance, either directly or
- 12 indirectly, by extraction from substances of natural origin,
- 13 independently by means of chemical synthesis, or by a combination of
- 14 extraction and chemical synthesis, and includes any packaging or
- 15 repackaging of the substance or labeling or relabeling of its container.
- 16 Manufacture does not include the preparation or compounding of a
- 17 controlled substance by an individual for his or her own use, except for
- 18 the preparation or compounding of components or ingredients used for or
- 19 intended to be used for the manufacture of methamphetamine, or the
- 20 preparation, compounding, conversion, packaging, or labeling of a
- 21 controlled substance: (a) By a practitioner as an incident to his or her
- 22 prescribing, administering, or dispensing of a controlled substance in
- 23 the course of his or her professional practice; or (b) by a practitioner,
- 24 or by his or her authorized agent under his or her supervision, for the
- 25 purpose of, or as an incident to, research, teaching, or chemical
- 26 analysis and not for sale;
- 27 (16) Narcotic drug means any of the following, whether produced
- 28 directly or indirectly by extraction from substances of vegetable origin,
- 29 independently by means of chemical synthesis, or by a combination of
- 30 extraction and chemical synthesis: (a) Opium, opium poppy and poppy
- 31 straw, coca leaves, and opiates; (b) a compound, manufacture, salt,

- 1 derivative, or preparation of opium, coca leaves, or opiates; or (c) a
- 2 substance and any compound, manufacture, salt, derivative, or preparation
- 3 thereof which is chemically equivalent to or identical with any of the
- 4 substances referred to in subdivisions (a) and (b) of this subdivision,
- 5 except that the words narcotic drug as used in the Uniform Controlled
- 6 Substances Act does not include decocainized coca leaves or extracts of
- 7 coca leaves, which extracts do not contain cocaine or ecgonine, or
- 8 isoquinoline alkaloids of opium;
- 9 (17) Opiate means any substance having an addiction-forming or
- 10 addiction-sustaining liability similar to morphine or being capable of
- 11 conversion into a drug having such addiction-forming or addiction-
- 12 sustaining liability. Opiate does not include the dextrorotatory isomer
- 13 of 3-methoxy-n methylmorphinan and its salts. Opiate includes its racemic
- 14 and levorotatory forms;
- 15 (18) Opium poppy means the plant of the species Papaver somniferum
- 16 L., except the seeds thereof;
- 17 (19) Poppy straw means all parts, except the seeds, of the opium
- 18 poppy after mowing;
- 19 (20) Person means any corporation, association, partnership, limited
- 20 liability company, or one or more persons;
- 21 (21) Practitioner means a physician, a physician assistant, a
- 22 dentist, a veterinarian, a pharmacist, a podiatrist, an optometrist, a
- 23 certified nurse midwife, a certified registered nurse anesthetist, a
- 24 nurse practitioner, a scientific investigator, a pharmacy, a hospital, or
- 25 any other person licensed, registered, or otherwise permitted to
- 26 distribute, dispense, prescribe, conduct research with respect to, or
- 27 administer a controlled substance in the course of practice or research
- 28 in this state, including an emergency medical service as defined in
- 29 section 38-1207;
- 30 (22) Production includes the manufacture, planting, cultivation, or
- 31 harvesting of a controlled substance;

1 (23) Immediate precursor means a substance which is the principal

- 2 compound commonly used or produced primarily for use and which is an
- 3 immediate chemical intermediary used or likely to be used in the
- 4 manufacture of a controlled substance, the control of which is necessary
- 5 to prevent, curtail, or limit such manufacture;
- 6 (24) State means the State of Nebraska;
- 7 (25) Ultimate user means a person who lawfully possesses a
- 8 controlled substance for his or her own use, for the use of a member of
- 9 his or her household, or for administration to an animal owned by him or
- 10 her or by a member of his or her household;
- 11 (26) Hospital has the same meaning as in section 71-419;
- 12 (27) Cooperating individual means any person, other than a
- 13 commissioned law enforcement officer, who acts on behalf of, at the
- 14 request of, or as agent for a law enforcement agency for the purpose of
- 15 gathering or obtaining evidence of offenses punishable under the Uniform
- 16 Controlled Substances Act;
- 17 (28)(a) Hashish or concentrated cannabis means (i) the separated
- 18 resin, whether crude or purified, obtained from a plant of the genus
- 19 cannabis or (ii) any material, preparation, mixture, compound, or other
- 20 substance which contains ten percent or more by weight of
- 21 tetrahydrocannabinols.
- 22 (b) When resins extracted from (i) industrial hemp as defined in
- 23 section 2-5701 are in the possession of a person as authorized under
- 24 section 2-5701 or (ii) hemp as defined in section 2-503 are in the
- 25 possession of a person as authorized under the Nebraska Hemp Farming Act,
- 26 they are not considered hashish or concentrated cannabis for purposes of
- 27 the Uniform Controlled Substances Act.
- 28 (c) Hashish or concentrated cannabis does not include cannabidiol
- 29 contained in a drug product approved by the federal Food and Drug
- 30 Administration;
- 31 <u>(28)</u> Exceptionally hazardous drug means (a) a narcotic drug,

1 (b) thiophene analog of phencyclidine, (c) phencyclidine, (d)

- 2 amobarbital, (e) secobarbital, (f) pentobarbital, (g) amphetamine, or (h)
- 3 methamphetamine;
- 4 (29) (30) Imitation controlled substance means a substance which is
- 5 not a controlled substance or controlled substance analogue but which, by
- 6 way of express or implied representations and consideration of other
- 7 relevant factors including those specified in section 28-445, would lead
- 8 a reasonable person to believe the substance is a controlled substance or
- 9 controlled substance analogue. A placebo or registered investigational
- 10 drug manufactured, distributed, possessed, or delivered in the ordinary
- 11 course of practice or research by a health care professional shall not be
- 12 deemed to be an imitation controlled substance;
- 13 (30)(a) (31)(a) Controlled substance analogue means a substance (i)
- 14 the chemical structure of which is substantially similar to the chemical
- 15 structure of a Schedule I or Schedule II controlled substance as provided
- 16 in section 28-405 or (ii) which has a stimulant, depressant, analgesic,
- 17 or hallucinogenic effect on the central nervous system that is
- 18 substantially similar to or greater than the stimulant, depressant,
- 19 analgesic, or hallucinogenic effect on the central nervous system of a
- 20 Schedule I or Schedule II controlled substance as provided in section
- 21 28-405. A controlled substance analogue shall, to the extent intended for
- 22 human consumption, be treated as a controlled substance under Schedule I
- 23 of section 28-405 for purposes of the Uniform Controlled Substances Act;
- 24 and
- 25 (b) Controlled substance analogue does not include (i) a controlled
- 26 substance, (ii) any substance generally recognized as safe and effective
- 27 within the meaning of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C.
- 28 301 et seq., as such act existed on January 1, 2014, (iii) any substance
- 29 for which there is an approved new drug application, or (iv) with respect
- 30 to a particular person, any substance if an exemption is in effect for
- 31 investigational use for that person, under section 505 of the Federal

- 1 Food, Drug, and Cosmetic Act, 21 U.S.C. 355, as such section existed on
- 2 January 1, 2014, to the extent conduct with respect to such substance is
- 3 pursuant to such exemption;
- 4 (31) (32) Anabolic steroid means any drug or hormonal substance,
- 5 chemically and pharmacologically related to testosterone (other than
- 6 estrogens, progestins, and corticosteroids), that promotes muscle growth
- 7 and includes any controlled substance in Schedule III(d) of section
- 8 28-405. Anabolic steroid does not include any anabolic steroid which is
- 9 expressly intended for administration through implants to cattle or other
- 10 nonhuman species and has been approved by the Secretary of Health and
- 11 Human Services for such administration, but if any person prescribes,
- 12 dispenses, or distributes such a steroid for human use, such person shall
- 13 be considered to have prescribed, dispensed, or distributed an anabolic
- 14 steroid within the meaning of this subdivision;
- 15 (32) (33) Chart order means an order for a controlled substance
- 16 issued by a practitioner for a patient who is in the hospital where the
- 17 chart is stored or for a patient receiving detoxification treatment or
- 18 maintenance treatment pursuant to section 28-412. Chart order does not
- 19 include a prescription;
- 20 (33) (34) Medical order means a prescription, a chart order, or an
- 21 order for pharmaceutical care issued by a practitioner;
- 22 (34) (35) Prescription means an order for a controlled substance
- 23 issued by a practitioner. Prescription does not include a chart order;
- 24 (35) (36) Registrant means any person who has a controlled
- 25 substances registration issued by the state or the Drug Enforcement
- 26 Administration of the United States Department of Justice;
- 27 (36) (37) Reverse distributor means a person whose primary function
- 28 is to act as an agent for a pharmacy, wholesaler, manufacturer, or other
- 29 entity by receiving, inventorying, and managing the disposition of
- 30 outdated, expired, or otherwise nonsaleable controlled substances;
- 31 (37) (38) Signature means the name, word, or mark of a person

- 1 written in his or her own hand with the intent to authenticate a writing
- 2 or other form of communication or a digital signature which complies with
- 3 section 86-611 or an electronic signature;
- 4 (38) (39) Facsimile means a copy generated by a system that encodes
- 5 a document or photograph into electrical signals, transmits those signals
- 6 over telecommunications lines, and reconstructs the signals to create an
- 7 exact duplicate of the original document at the receiving end;
- 8 (39) (40) Electronic signature has the definition found in section
- 9 86-621;
- 10 (40) (41) Electronic transmission means transmission of information
- in electronic form. Electronic transmission includes computer-to-computer
- 12 transmission or computer-to-facsimile transmission;
- 13 (41) (42) Long-term care facility means an intermediate care
- 14 facility, an intermediate care facility for persons with developmental
- 15 disabilities, a long-term care hospital, a mental health substance use
- 16 treatment center, a nursing facility, or a skilled nursing facility, as
- 17 such terms are defined in the Health Care Facility Licensure Act;
- 18 (42) (43) Compounding has the same meaning as in section 38-2811;
- 19 (43) (44) Cannabinoid receptor agonist means any chemical compound
- 20 or substance that, according to scientific or medical research, study,
- 21 testing, or analysis, demonstrates the presence of binding activity at
- 22 one or more of the CB1 or CB2 cell membrane receptors located within the
- 23 human body. Cannabinoid receptor agonist does not include cannabidiol
- 24 contained in a drug product approved by the federal Food and Drug
- 25 Administration; and
- 26 (44) (45) Lookalike substance means a product or substance, not
- 27 specifically designated as a controlled substance in section 28-405, that
- 28 is either portrayed in such a manner by a person to lead another person
- 29 to reasonably believe that it produces effects on the human body that
- 30 replicate, mimic, or are intended to simulate the effects produced by a
- 31 controlled substance or that possesses one or more of the following

- 1 indicia or characteristics:
- 2 (a) The packaging or labeling of the product or substance suggests
- 3 that the user will achieve euphoria, hallucination, mood enhancement,
- 4 stimulation, or another effect on the human body that replicates or
- 5 mimics those produced by a controlled substance;
- 6 (b) The name or packaging of the product or substance uses images or
- 7 labels suggesting that it is a controlled substance or produces effects
- 8 on the human body that replicate or mimic those produced by a controlled
- 9 substance;
- 10 (c) The product or substance is marketed or advertised for a
- 11 particular use or purpose and the cost of the product or substance is
- 12 disproportionately higher than other products or substances marketed or
- 13 advertised for the same or similar use or purpose;
- 14 (d) The packaging or label on the product or substance contains
- 15 words or markings that state or suggest that the product or substance is
- 16 in compliance with state and federal laws regulating controlled
- 17 substances;
- 18 (e) The owner or person in control of the product or substance uses
- 19 evasive tactics or actions to avoid detection or inspection of the
- 20 product or substance by law enforcement authorities;
- 21 (f) The owner or person in control of the product or substance makes
- 22 a verbal or written statement suggesting or implying that the product or
- 23 substance is a synthetic drug or that consumption of the product or
- 24 substance will replicate or mimic effects on the human body to those
- 25 effects commonly produced through use or consumption of a controlled
- 26 substance;
- 27 (g) The owner or person in control of the product or substance makes
- 28 a verbal or written statement to a prospective customer, buyer, or
- 29 recipient of the product or substance implying that the product or
- 30 substance may be resold for profit; or
- 31 (h) The product or substance contains a chemical or chemical

1 compound that does not have a legitimate relationship to the use or

- 2 purpose claimed by the seller, distributor, packer, or manufacturer of
- 3 the product or substance or indicated by the product name, appearing on
- 4 the product's packaging or label or depicted in advertisement of the
- 5 product or substance.
- 6 Sec. 5. Section 28-405, Revised Statutes Cumulative Supplement,
- 7 2022, is amended to read:
- 8 28-405 The following are the schedules of controlled substances
- 9 referred to in the Uniform Controlled Substances Act, unless specifically
- 10 contained on the list of exempted products of the Drug Enforcement
- 11 Administration of the United States Department of Justice as the list
- 12 existed on January 31, 2021:
- 13 Schedule I
- 14 (a) Any of the following opiates, including their isomers, esters,
- 15 ethers, salts, and salts of isomers, esters, and ethers, unless
- 16 specifically excepted, whenever the existence of such isomers, esters,
- 17 ethers, and salts is possible within the specific chemical designation:
- 18 (1) Acetylmethadol;
- 19 (2) Allylprodine;
- 20 (3) Alphacetylmethadol, except levo-alphacetylmethadol which is also
- 21 known as levo-alpha-acetylmethadol, levomethadyl acetate, and LAAM;
- 22 (4) Alphameprodine;
- 23 (5) Alphamethadol;
- 24 (6) Benzethidine;
- 25 (7) Betacetylmethadol;
- 26 (8) Betameprodine;
- 27 (9) Betamethadol;
- 28 (10) Betaprodine;
- 29 (11) Clonitazene;
- 30 (12) Dextromoramide;
- 31 (13) Difenoxin;

```
LB22
                                                                                LB22
2023
                                                                                2023
 1
           (14) Diampromide;
  2
           (15) Diethylthiambutene;
  3
           (16) Dimenoxadol;
  4
           (17) Dimepheptanol;
  5
           (18) Dimethylthiambutene;
  6
           (19) Dioxaphetyl butyrate;
  7
           (20) Dipipanone;
  8
           (21) Ethylmethylthiambutene;
  9
           (22) Etonitazene;
 10
           (23) Etoxeridine;
 11
           (24) Furethidine;
 12
           (25) Hydroxypethidine;
 13
           (26) Ketobemidone;
 14
           (27) Levomoramide;
 15
           (28) Levophenacylmorphan;
 16
           (29) Morpheridine;
 17
           (30) Noracymethadol;
 18
           (31) Norlevorphanol;
 19
           (32) Normethadone;
 20
           (33) Norpipanone;
           (34) Phenadoxone;
 21
 22
           (35) Phenampromide;
 23
           (36) Phenomorphan;
 24
           (37) Phenoperidine;
 25
           (38) Piritramide;
 26
           (39) Proheptazine;
 27
           (40) Properidine;
 28
           (41) Propiram;
 29
           (42) Racemoramide;
 30
           (43) Trimeperidine;
 31
           (44) Alpha-methylfentanyl, N-(1-(alpha-methyl-beta-phenyl)ethyl-4-
```

LB22 LB22

2023 2023

- piperidyl) propionanilide, 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) 1
- 2 piperidine;
- 3 (45) Tilidine;
- (46) 3-Methylfentanyl, N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-4
- 5 phenylpropanamide, its optical and geometric isomers, salts, and salts of
- 6 isomers;
- 7 (47) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its optical
- 8 isomers, salts, and salts of isomers;
- 9 (48) PEPAP, 1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine, its
- 10 optical isomers, salts, and salts of isomers;
- (49) Acetyl-alpha-methylfentanyl, N-(1-(1-methyl-2-phenethyl)-4-11
- piperidinyl)-N-phenylacetamide, its optical isomers, salts, and salts of 12
- 13 isomers;
- Alpha-methylthiofentanyl, N-(1-methyl-2-(2-thienyl)ethyl-4-14 (50)
- piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts 15
- 16 of isomers;
- 17 (51) Benzylfentanyl, N-(1-benzyl-4-piperidyl)-N-phenylpropanamide,
- its optical isomers, salts, and salts of isomers; 18
- 19 Beta-hydroxyfentanyl, N-(1-(2-hydroxy-2-phenethyl)-4-(52)
- piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts 20
- of isomers; 21
- 22 (53) Beta-hydroxy-3-methylfentanyl, (other name: N-(1-(2-hydroxy-2-
- 23 phenethyl)-3-methyl-4-piperidinyl)-N-phenylpropanamide), its optical and
- geometric isomers, salts, and salts of isomers; 24
- (54) 25 3-methylthiofentanyl, N-(3-methyl-1-(2-thienyl)ethyl-4-
- piperidinyl)-N-phenylpropanamide, its optical and geometric isomers, 26
- 27 salts, and salts of isomers;
- (55)28 N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide
- (thenylfentanyl), its optical isomers, salts, and salts of isomers; 29
- 30 (56)Thiofentanyl, N-phenyl-N-(1-(2-thienyl)ethyl-4-piperidinyl)-
- propanamide, its optical isomers, salts, and salts of isomers; 31

```
LB22
                                                                             LB22
2023
                                                                             2023
 1
           (57)
                 Para-fluorofentanyl, N-(4-fluorophenyl)-N-(1-(2-phenethyl)-4-
  2
      piperidinyl)propanamide, its optical isomers, salts, and salts of
  3
      isomers;
  4
           (58)
                    U-47700,
                                 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-
  5
      methylbenzamide;
  6
           (59) 4-Fluoroisobutyryl Fentanyl;
  7
           (60) Acetyl Fentanyl;
  8
           (61) Acyrloylfentanyl;
  9
           (62) AH-7921; 3, 4-dichloro-N-[(1-dimethylamino) cyclohexylmethyl]
 10
      benzamide;
           (63) Butyryl fentanyl;
 11
 12
           (64) Cyclopentyl fentanyl;
 13
           (65) Cyclopropyl fentanyl;
           (66) Furanyl fentanyl;
 14
 15
           (67) Isobutyryl fentanyl;
 16
           (68) Isotonitazene;
 17
           (69) Methoxyacetyl fentanyl;
           (70) MT-45; 1-cyclohexyl-4-(1,2-diphenylethyl) piperazine;
 18
 19
           (71) Tetrahydrofuranyl fentanyl;
           (72) 2-fluorofentanyl; N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-
 20
 21
      yl) propionamide;
 22
           (73) Ocfentanil;
 23
           (74) Ortho-Fluorofentanyl;
 24
           (75) Para-chloroisobutyryl fentanyl;
 25
           (76) Para-Fluorobutyryl Fentanyl;
           (77) Valeryl fentanyl;
 26
 27
           (78) Phenyl Fentanyl;
 28
           (79) Para-Methylfentanyl;
 29
           (80) Thiofuranyl Fentanyl;
 30
           (81) Beta-methyl Fentanyl;
 31
           (82) Beta'-Phenyl Fentanyl;
```

```
LB22
                                                                              LB22
2023
                                                                              2023
  1
           (83) Crotonyl Fentanyl;
  2
           (84) 2'-Fluoro Ortho-Fluorofentanyl;
  3
           (85) 4'-Methyl Acetyl Fentanyl;
  4
           (86) Ortho-Fluorobutyryl Fentanyl;
  5
           (87) Ortho-Methyl Acetylfentanyl;
  6
           (88) Ortho-Methyl Methoxyacetyl Fentanyl;
  7
           (89) Ortho-Fluoroacryl Fentanyl;
  8
           (90) Fentanyl Carbamate;
 9
           (91) Ortho-Fluoroisobutyryl Fentanyl;
 10
           (92) Para-Fluoro Furanyl Fentanyl;
           (93) Para-Methoxybutyryl Fentanyl; and
 11
 12
           (94)
                  Brorphine
                               (other
                                                 1 - (1 - (1 - (4 - bromophenyl))
                                                                            ethyl)
                                        name:
 13
      piperidin-4-yl-1, 3-dihydro-2H-benzo[D]imidazole-2-one).
           (b) Any of the following opium derivatives, their salts, isomers,
 14
 15
           salts of isomers,
                                 unless specifically excepted,
                                                                    whenever the
 16
      existence of such salts, isomers, and salts of isomers is possible within
 17
      the specific chemical designation:
 18
           (1) Acetorphine;
 19
           (2) Acetyldihydrocodeine;
           (3) Benzylmorphine;
 20
 21
           (4) Codeine methylbromide;
 22
           (5) Codeine-N-Oxide;
 23
           (6) Cyprenorphine;
 24
           (7) Desomorphine;
 25
           (8) Dihydromorphine;
           (9) Drotebanol;
 26
           (10) Etorphine, except hydrochloride salt;
 27
 28
           (11) Heroin;
           (12) Hydromorphinol;
 29
 30
           (13) Methyldesorphine;
           (14) Methyldihydromorphine;
 31
```

- 1 (15) Morphine methylbromide;
- 2 (16) Morphine methylsulfonate;
- 3 (17) Morphine-N-Oxide;
- 4 (18) Myrophine;
- 5 (19) Nicocodeine;
- 6 (20) Nicomorphine;
- 7 (21) Normorphine;
- 8 (22) Pholcodine; and
- 9 (23) Thebacon.
- 10 (c) Any material, compound, mixture, or preparation which contains
- 11 any quantity of the following hallucinogenic substances, their salts,
- 12 isomers, and salts of isomers, unless specifically excepted, whenever the
- 13 existence of such salts, isomers, and salts of isomers is possible within
- 14 the specific chemical designation, and, for purposes of this subdivision
- only, isomer shall include the optical, position, and geometric isomers:
- 16 (1) Bufotenine. Trade and other names shall include, but are not
- 17 limited to: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-
- 18 dimethylaminoethyl)-5-indolol; N,N-dimethylserotonin; 5-hydroxy-N,N-
- 19 dimethyltryptamine; and mappine;
- 20 (2) 4-bromo-2,5-dimethoxyamphetamine. Trade and other names shall
- 21 include, but are not limited to: 4-bromo-2,5-dimethoxy-alpha-
- 22 methylphenethylamine; and 4-bromo-2,5-DMA;
- 23 (3) 4-methoxyamphetamine. Trade and other names shall include, but
- 24 are not limited to: 4-methoxy-alpha-methylphenethylamine; and
- 25 paramethoxyamphetamine, PMA;
- 26 (4) 4-methyl-2,5-dimethoxyamphetamine. Trade and other names shall
- 27 include, but are not limited to: 4-methyl-2,5-dimethoxy-alpha-
- 28 methylphenethylamine; DOM; and STP;
- 29 (5) Para-methoxymethamphetamine. Trade and other names shall
- 30 include, but are not limited to: 1-(4-Methoxyphenyl)-N-methylpropan-2-
- 31 amine, PMMA, and 4-MMA;

1 (6) Ibogaine. Trade and other names shall include, but are not

- 2 limited to: 7-Ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9-
- 3 methano-5H-pyrido (1',2':1,2) azepino (5,4-b) indole; and Tabernanthe
- 4 iboga;
- 5 (7) Lysergic acid diethylamide;
- 6 (8) Marijuana;
- 7 (9) Mescaline;
- 8 (10) Peyote. Peyote shall mean all parts of the plant presently
- 9 classified botanically as Lophophora williamsii Lemaire, whether growing
- 10 or not, the seeds thereof, any extract from any part of such plant, and
- 11 every compound, manufacture, salts, derivative, mixture, or preparation
- 12 of such plant or its seeds or extracts;
- 13 (11) Psilocybin;
- 14 (12) Psilocyn;
- 15 (13) Synthetic tetrahydrocannabinols Tetrahydrocannabinols,
- 16 including, but not limited to, synthetic equivalents of the substances
- 17 contained in the plant or in the resinous extractives of cannabis, sp. or
- 18 synthetic substances, derivatives, and their isomers with similar
- 19 chemical structure and pharmacological activity such as the following:
- 20 Delta 1 cis or trans tetrahydrocannabinol and their optical isomers,
- 21 excluding dronabinol in a drug product approved by the federal Food and
- 22 Drug Administration; Delta 6 cis or trans tetrahydrocannabinol and their
- 23 optical isomers; and Delta 3,4 cis or trans tetrahydrocannabinol and its
- 24 optical isomers. Since nomenclature of these substances is not
- 25 internationally standardized, compounds of these structures shall be
- 26 included regardless of the numerical designation of atomic positions
- 27 covered. Tetrahydrocannabinols does not include cannabidiol contained in
- 28 a drug product approved by the federal Food and Drug Administration or
- 29 <u>naturally occurring tetrahydrocannabinols extracted or derived from</u>
- 30 <u>marijuana</u>;
- 31 (14) N-ethyl-3-piperidyl benzilate;

- 1 (15) N-methyl-3-piperidyl benzilate;
- 2 (16) Thiophene analog of phencyclidine. Trade and other names shall
- 3 include, but are not limited to: 1-(1-(2-thienyl)-cyclohexyl)-piperidine;
- 4 2-thienyl analog of phencyclidine; TPCP; and TCP;
- 5 (17) Hashish or concentrated cannabis;
- 6 (17) (18) Parahexyl. Trade and other names shall include, but are
- 7 not limited to: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
- 8 dibenzo(b,d)pyran; and Synhexyl;
- 9 (18) (19) Ethylamine analog of phencyclidine. Trade and other names
- 10 shall include, but are not limited to: N-ethyl-1-phenylcyclohexylamine;
- 11 (1-phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)ethylamine;
- 12 cyclohexamine; and PCE;
- 13 (19) (20) Pyrrolidine analog of phencyclidine. Trade and other names
- 14 shall include, but are not limited to: 1-(1-phenylcyclohexyl)-
- 15 pyrrolidine; PCPy; and PHP;
- 16 (20) (21) Alpha-ethyltryptamine. Some trade or other names:
- 17 etryptamine; Monase; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl)
- 18 indole; alpha-ET; and AET;
- 19 (21) (22) 2,5-dimethoxy-4-ethylamphet-amine; and DOET;
- 20 (22) (23) 1-(1-(2-thienyl)cyclohexyl)pyrrolidine; and TCPy;
- 21 (23) (24) Alpha-methyltryptamine, which is also known as AMT;
- 22 (24) (25) Salvia divinorum or Salvinorin A. Salvia divinorum or
- 23 Salvinorin A includes all parts of the plant presently classified
- 24 botanically as Salvia divinorum, whether growing or not, the seeds
- 25 thereof, any extract from any part of such plant, and every compound,
- 26 manufacture, derivative, mixture, or preparation of such plant, its
- 27 seeds, or its extracts, including salts, isomers, and salts of isomers
- 28 whenever the existence of such salts, isomers, and salts of isomers is
- 29 possible within the specific chemical designation;
- 30 (25) (26) Any material, compound, mixture, or preparation containing
- 31 any quantity of synthetically produced cannabinoids as listed in

- 1 subdivisions (A) through (L) of this subdivision, including their salts,
- 2 isomers, salts of isomers, and nitrogen, oxygen, or sulfur-heterocyclic
- 3 analogs, unless specifically excepted elsewhere in this section. Since
- 4 nomenclature of these synthetically produced cannabinoids is not
- 5 internationally standardized and may continually evolve, these structures
- 6 or compounds of these structures shall be included under this
- 7 subdivision, regardless of their specific numerical designation of atomic
- 8 positions covered, so long as it can be determined through a recognized
- 9 method of scientific testing or analysis that the substance contains
- 10 properties that fit within one or more of the following categories:
- 11 (A) Tetrahydrocannabinols: Meaning <u>synthetic equivalents of</u>
- 12 tetrahydrocannabinols naturally contained in a plant of the genus
- 13 cannabis (cannabis plant), as well as synthetic equivalents of the
- 14 substances contained in the plant, or in the resinous extractives of
- 15 cannabis, sp. and/or synthetic substances, derivatives, and their isomers
- 16 with similar chemical structure and pharmacological activity such as the
- 17 following: Delta 1 cis or trans tetrahydrocannabinol, and their optical
- 18 isomers; Delta 6 cis or trans tetrahydrocannabinol, and their optical
- 19 isomers; Delta 3,4 cis or trans tetrahydrocannabinol, and its optical
- 20 isomers. This subdivision does not include cannabidiol contained in a
- 21 drug product approved by the federal Food and Drug Administration;
- 22 (B) Naphthoylindoles: Any compound containing a 3-(1-
- 23 naphthoyl)indole structure with substitution at the nitrogen atom of the
- 24 indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
- 25 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
- 26 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
- 27 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
- 28 tetrahydropyranylmethyl group, whether or not further substituted in or
- 29 on any of the listed ring systems to any extent;
- 30 (C) Naphthylmethylindoles: Any compound containing a 1 H-indol-3-
- 31 yl-(1-naphthyl)methane structure with substitution at the nitrogen atom

- 1 of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
- 2 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
- 3 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
- 4 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
- 5 tetrahydropyranylmethyl group, whether or not further substituted in or
- 6 on any of the listed ring systems to any extent;
- 7 (D) Naphthoylpyrroles: Any compound containing a 3-(1-
- 8 naphthoyl)pyrrole structure with substitution at the nitrogen atom of the
- 9 pyrrole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
- 10 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
- 11 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
- 12 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
- 13 tetrahydropyranylmethyl group, whether or not further substituted in or
- on any of the listed ring systems to any extent;
- 15 (E) Naphthylideneindenes: Any compound containing a
- 16 naphthylideneindene structure with substitution at the 3-position of the
- 17 indene ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
- 18 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
- 19 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
- 20 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
- 21 tetrahydropyranylmethyl group, whether or not further substituted in or
- 22 on any of the listed ring systems to any extent;
- 23 (F) Phenylacetylindoles: Any compound containing a 3-
- 24 phenylacetylindole structure with substitution at the nitrogen atom of
- 25 the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
- 26 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
- 27 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
- 28 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
- 29 tetrahydropyranylmethyl group, whether or not further substituted in or
- 30 on any of the listed ring systems to any extent;
- 31 (G) Cyclohexylphenols: Any compound containing a 2-(3-

- 1 hydroxycyclohexyl)phenol structure with substitution at the 5-position of
- 2 the phenolic ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
- 3 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
- 4 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
- 5 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
- 6 tetrahydropyranylmethyl group, whether or not substituted in or on any of
- 7 the listed ring systems to any extent;
- 8 (H) Benzoylindoles: Any compound containing a 3-(benzoyl)indole
- 9 structure with substitution at the nitrogen atom of the indole ring by an
- 10 alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl,
- cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-
- 12 piperidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
- 13 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not
- 14 further substituted in or on any of the listed ring systems to any
- 15 extent;
- 16 (I) Adamantoylindoles: Any compound containing a 3-adamantoylindole
- 17 structure with substitution at the nitrogen atom of the indole ring by an
- 18 alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl,
- 19 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl,
- 20 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
- 21 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not
- 22 further substituted in or on any of the listed ring systems to any
- 23 extent;
- 24 (J) Tetramethylcyclopropanoylindoles: Any compound containing a 3-
- 25 tetramethylcyclopropanoylindole structure with substitution at the
- 26 nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,
- 27 alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-
- 28 methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
- 29 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
- 30 tetrahydropyranylmethyl group, whether or not further substituted in or
- 31 on any of the listed ring systems to any extent;

31

LB22 2023

1 (K) Indole carboxamides: Any compound containing a 1-indole-3carboxamide structure with substitution at the nitrogen atom of the 2 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, 3 4 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-5 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, 6 or tetrahydropyranylmethyl group, substitution at the carboxamide group by 7 methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl, 8 an alkyl, 9 phenyl, aminooxoalkyl group, or quinolinyl group, whether or not further substituted in or on any of the listed ring systems to any extent or to 10 11 the adamantyl, 1-mapthyl, phenyl, aminooxoalkyl, benzyl, or propionaldehyde groups to any extent; 12 (L) Indole carboxylates: Any compound containing a 1-indole-3-13 carboxylate structure with substitution at the nitrogen atom of the 14 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, 15 16 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-17 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, 18 tetrahydropyranylmethyl group, substitution at the carboxylate group by 19 benzyl, propionaldehyde, adamantyl, 1-naphthyl, methoxy, 20 alkyl, phenyl, aminooxoalkyl group, or quinolinyl group, whether or not further 21 substituted in or on any of the listed ring systems to any extent or to 22 23 adamantyl, 1-mapthyl, phenyl, aminooxoalkyl, benzyl, the or 24 propionaldehyde groups to any extent; and 25 (M) Any nonnaturally occurring substance, chemical compound, mixture, or preparation, not specifically listed elsewhere in these 26 schedules and which is not approved for human consumption by the federal 27 Food and Drug Administration, containing or constituting a cannabinoid 28 receptor agonist as defined in section 28-401. This subdivision (M) does 29 not apply to any product or preparation containing solely 30

tetrahydrocannabinols which are naturally occurring and extracted or

- 1 derived from marijuana;
- 2 (26) (27) Any material, compound, mixture, or preparation containing
- 3 any quantity of a substituted phenethylamine as listed in subdivisions
- 4 (A) through (C) of this subdivision, unless specifically excepted, listed
- 5 in another schedule, or specifically named in this schedule, that is
- 6 structurally derived from phenylethan-2-amine by substitution on the
- 7 phenyl ring with a fused methylenedioxy ring, fused furan ring, or a
- 8 fused tetrahydrofuran ring; by substitution with two alkoxy groups; by
- 9 substitution with one alkoxy and either one fused furan, tetrahydrofuran,
- 10 or tetrahydropyran ring system; or by substitution with two fused ring
- 11 systems from any combination of the furan, tetrahydrofuran, or
- 12 tetrahydropyran ring systems, whether or not the compound is further
- 13 modified in any of the following ways:
- 14 (A) Substitution of the phenyl ring by any halo, hydroxyl, alkyl,
- 15 trifluoromethyl, alkoxy, or alkylthio groups; (B) substitution at the 2-
- 16 position by any alkyl groups; or (C) substitution at the 2-amino nitrogen
- 17 atom with alkyl, dialkyl, benzyl, hydroxybenzyl or methoxybenzyl groups,
- 18 and including, but not limited to:
- 19 (i) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine, which is also known
- 20 as 2C-C or 2,5-Dimethoxy-4-chlorophenethylamine;
- 21 (ii) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine, which is also known
- 22 as 2C-D or 2,5-Dimethoxy-4-methylphenethylamine;
- 23 (iii) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine, which is also known
- 24 as 2C-E or 2,5-Dimethoxy-4-ethylphenethylamine;
- 25 (iv) 2-(2,5-Dimethoxyphenyl)ethanamine, which is also known as 2C-H
- or 2,5-Dimethoxyphenethylamine;
- 27 (v) 2-(4-lodo-2,5-dimethoxyphenyl)ethanamine, which is also known as
- 28 2C-I or 2,5-Dimethoxy-4-iodophenethylamine;
- 29 (vi) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine, which is also known
- 30 as 2C-N or 2,5-Dimethoxy-4-nitrophenethylamine;
- 31 (vii) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine, which is also

- 1 known as 2C-P or 2,5-Dimethoxy-4-propylphenethylamine;
- 2 (viii) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine, which is
- 3 also known as 2C-T-2 or 2,5-Dimethoxy-4-ethylthiophenethylamine;
- 4 (ix) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine, which is
- 5 also known as 2C-T-4 or 2,5-Dimethoxy-4-isopropylthiophenethylamine;
- 6 (x) 2-(4-bromo-2,5-dimethoxyphenyl)ethanamine, which is also known
- 7 as 2C-B or 2,5-Dimethoxy-4-bromophenethylamine;
- 8 (xi) 2-(2,5-dimethoxy-4-(methylthio)phenyl)ethanamine, which is also
- 9 known as 2C-T or 4-methylthio-2,5-dimethoxyphenethylamine;
- 10 (xii) 1-(2,5-dimethoxy-4-iodophenyl)-propan-2-amine, which is also
- 11 known as DOI or 2,5-Dimethoxy-4-iodoamphetamine;
- 12 (xiii) 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopropane, which is also
- 13 known as DOB or 2,5-Dimethoxy-4-bromoamphetamine;
- 14 (xiv) 1-(4-chloro-2,5-dimethoxy-phenyl)propan-2-amine, which is also
- 15 known as DOC or 2,5-Dimethoxy-4-chloroamphetamine;
- 16 (xv) 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-
- 17 methoxyphenyl)methyl]ethanamine, which is also known as 2C-B-NBOMe; 25B-
- 18 NBOMe or 2,5-Dimethoxy-4-bromo-N-(2-methoxybenzyl)phenethylamine;
- 19 (xvi) 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-iodo-2,5-dimethoxyphenyl)]
- 20 methoxyphenyl)methyl]ethanamine, which is also known as 2C-I-NBOMe; 25I-
- 21 NBOMe or 2,5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine;
- 22 (xvii) N-(2-Methoxybenzyl)-2-(3,4,5-trimethoxyphenyl)ethanamine,
- 23 which is also known as Mescaline-NBOMe or 3,4,5-trimethoxy-N-(2-
- 24 methoxybenzyl)phenethylamine;
- 25 (xviii) 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-
- 26 methoxyphenyl)methyl]ethanamine, which is also known as 2C-C-NBOMe; or
- 27 25C-NBOMe or 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine;
- 28 (xix) 2-(7-Bromo-5-methoxy-2,3-dihydro-1-benzofuran-4-yl)ethanamine,
- 29 which is also known as 2CB-5-hemiFLY;
- 30 (xx) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-
- 31 yl)ethanamine, which is also known as 2C-B-FLY;

1 (xxi) 2-(10-Bromo-2, 3, 4, 7, 8, 9-hexahydropyrano[2, 3-g]chromen-5-

- 2 yl)ethanamine, which is also known as 2C-B-butterFLY;
- 3 (xxii) N-(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7-tetrahydrobenzo[1,2-
- 4 b:4,5-b']difuran-4-yl)-2-aminoethane, which is also known as 2C-B-FLY-
- 5 NBOMe;
- 6 (xxiii) 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine,
- 7 which is also known as bromo-benzodifuranylisopropylamine or bromo-
- 8 dragonFLY;
- 9 (xxiv) N-(2-Hydroxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine, which
- 10 is also known as 2C-INBOH or 25I-NBOH;
- 11 (xxv) 5-(2-Aminopropyl)benzofuran, which is also known as 5-APB;
- 12 (xxvi) 6-(2-Aminopropyl)benzofuran, which is also known as 6-APB;
- 13 (xxvii) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also known
- 14 as 5-APDB;
- 15 (xxviii) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also
- 16 known as 6-APDB;
- 17 (xxix) 2,5-dimethoxy-amphetamine, which is also known as 2, 5-
- 18 dimethoxy-a-methylphenethylamine; 2, 5-DMA;
- 19 (xxx) 2,5-dimethoxy-4-ethylamphetamine, which is also known as DOET;
- 20 (xxxi) 2,5-dimethoxy-4-(n)-propylthiophenethylamine, which is also
- 21 known as 2C-T-7;
- 22 (xxxii) 5-methoxy-3,4-methylenedioxy-amphetamine;
- 23 (xxxiii) 4-methyl-2,5-dimethoxy-amphetamine, which is also known as
- 4-methyl-2,5-dimethoxy-amethylphenethylamine; DOM and STP;
- 25 (xxxiv) 3,4-methylenedioxy amphetamine, which is also known as MDA;
- 26 (xxxv) 3,4-methylenedioxymethamphetamine, which is also known as
- 27 MDMA;
- 28 (xxxvi) 3,4-methylenedioxy-N-ethylamphetamine, which is also known
- 29 as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, MDE, MDEA;
- 30 (xxxvii) 3,4,5-trimethoxy amphetamine; and
- 31 (xxxviii) n-hydroxy-3.4-Methylenedioxy-N-Hydroxyamphetamine, which

- 1 is also known as N-hydroxyMDA;
- 2 (27) (28) Any material, compound, mixture, or preparation containing
- 3 any quantity of a substituted tryptamine unless specifically excepted,
- 4 listed in another schedule, or specifically named in this schedule, that
- 5 is structurally derived from 2-(1H-indol-3-yl)ethanamine, which is also
- 6 known as tryptamine, by mono- or di-substitution of the amine nitrogen
- 7 with alkyl or alkenyl groups or by inclusion of the amino nitrogen atom
- 8 in a cyclic structure whether or not the compound is further substituted
- 9 at the alpha position with an alkyl group or whether or not further
- 10 substituted on the indole ring to any extent with any alkyl, alkoxy,
- 11 halo, hydroxyl, or acetoxy groups, and including, but not limited to:
- 12 (A) 5-methoxy-N,N-diallyltryptamine, which is also known as 5-MeO-
- 13 DALT;
- 14 (B) 4-acetoxy-N, N-dimethyltryptamine, which is also known as 4-AcO-
- 15 DMT or OAcetylpsilocin;
- 16 (C) 4-hydroxy-N-methyl-N-ethyltryptamine, which is also known as 4-
- 17 HO-MET;
- 18 (D) 4-hydroxy-N,N-diisopropyltryptamine, which is also known as 4-
- 19 HO-DIPT;
- 20 (E) 5-methoxy-N-methyl-N-isopropyltryptamine, which is also known as
- 21 5-MeOMiPT;
- 22 (F) 5-Methoxy-N,N-Dimethyltryptamine, which is also known as 5-MeO-
- 23 DMT;
- 24 (G) 5-methoxy-N,N-diisopropyltryptamine, which is also known as 5-
- 25 MeO-DiPT;
- 26 (H) Diethyltryptamine, which is also known as N,N-Diethyltryptamine,
- 27 DET; and
- 28 (I) Dimethyltryptamine, which is also known as DMT; and
- 29 (28)(A) (29)(A) Any substance containing any quantity of the
- 30 following materials, compounds, mixtures, or structures:
- 31 (i) 3,4-methylenedioxymethcathinone, or bk-MDMA, or methylone;

- 1 (ii) 3,4-methylenedioxypyrovalerone, or MDPV;
- 2 (iii) 4-methylmethcathinone, or 4-MMC, or mephedrone;
- 3 (iv) 4-methoxymethcathinone, or bk-PMMA, or PMMC, or methedrone;
- 4 (v) Fluoromethcathinone, or FMC;
- 5 (vi) Naphthylpyrovalerone, or naphyrone; or
- 6 (vii) Beta-keto-N-methylbenzodioxolylpropylamine or bk-MBDB or
- 7 butylone; or
- 8 (B) Unless listed in another schedule, any substance which contains
- 9 any quantity of any material, compound, mixture, or structure, other than
- 10 bupropion, that is structurally derived by any means from 2-
- 11 aminopropan-1-one by substitution at the 1-position with either phenyl,
- 12 naphthyl, or thiophene ring systems, whether or not the compound is
- 13 further modified in any of the following ways:
- 14 (i) Substitution in the ring system to any extent with alkyl,
- 15 alkoxy, alkylenedioxy, haloalkyl, hydroxyl, or halide substituents,
- 16 whether or not further substituted in the ring system by one or more
- 17 other univalent substituents;
- 18 (ii) Substitution at the 3-position with an acyclic alkyl
- 19 substituent; or
- 20 (iii) Substitution at the 2-amino nitrogen atom with alkyl or
- 21 dialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic
- 22 structure.
- 23 (d) Unless specifically excepted or unless listed in another
- 24 schedule, any material, compound, mixture, or preparation which contains
- 25 any quantity of the following substances having a depressant effect on
- 26 the central nervous system, including its salts, isomers, and salts of
- 27 isomers whenever the existence of such salts, isomers, and salts of
- 28 isomers is possible within the specific chemical designation:
- 29 (1) Mecloqualone;
- 30 (2) Methaqualone; and
- 31 (3) Gamma-Hydroxybutyric Acid. Some other names include: GHB; Gamma-

1 hydroxybutyrate; 4-Hydroxybutyrate; 4-Hydroxybutanoic Acid; Sodium

- 2 Oxybate; and Sodium Oxybutyrate.
- 3 (e) Unless specifically excepted or unless listed in another
- 4 schedule, any material, compound, mixture, or preparation which contains
- 5 any quantity of the following substances having a stimulant effect on the
- 6 central nervous system, including its salts, isomers, and salts of
- 7 isomers:
- 8 (1) Fenethylline;
- 9 (2) N-ethylamphetamine;
- 10 (3) Aminorex; aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or 4,5-
- dihydro-5-phenyl-2-oxazolamine;
- 12 (4) Cathinone; 2-amino-1-phenyl-1-propanone; alpha-
- aminopropiophenone; 2-aminopropiophenone; and norephedrone;
- 14 (5) Methcathinone, its salts, optical isomers, and salts of optical
- 15 isomers. Some other names: 2-(methylamino)-propiophenone; alpha-
- 16 (methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-
- 17 N-methylaminopropiophenone; methylcathinone; monomethylpropion;
- ephedrone; N-methylcathinone; AL-464; AL-422; AL-463; UR1432; and 4-MEC;
- 19 (6) (+/-)cis-4-methylaminorex; and (+/-)cis-4,5-dihydro-4-methyl-5-
- 20 phenyl-2-oxazolamine;
- 21 (7) N,N-dimethylamphetamine; N,N-alpha-trimethyl-benzeneethanamine;
- 22 and N, N-alpha-trimethylphenethylamine;
- 23 (8) Benzylpiperazine, 1-benzylpiperazine; and
- 24 (9) 4,4'-dimethylaminorex (other names: 4,4'-DMAR, 4,5-dihydro-4-
- 25 methyl-5-(4-methylphenyl)-2-oxazolamine).
- 26 (f) Any controlled substance analogue to the extent intended for
- 27 human consumption.
- 28 Schedule II
- 29 (a) Any of the following substances except those narcotic drugs
- 30 listed in other schedules whether produced directly or indirectly by
- 31 extraction from substances of vegetable origin, independently by means of

LB22 LB22

2023 2023

- 1 chemical synthesis, or by combination of extraction and chemical
- 2 synthesis:
- 3 (1) Opium and opiate, and any salt, compound, derivative,
- preparation of opium or opiate, excluding apomorphine, buprenorphine, 4
- 5 thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene,
- 6 naloxone, and naltrexone and their salts, but including the following:
- 7 (A) Raw opium;
- 8 (B) Opium extracts;
- 9 (C) Opium fluid;
- (D) Powdered opium; 10
- (E) Granulated opium; 11
- (F) Tincture of opium; 12
- 13 (G) Codeine;
- (H) Ethylmorphine; 14
- (I) Etorphine hydrochloride; 15
- 16 (J) Hydrocodone;
- 17 (K) Hydromorphone;
- 18 (L) Metopon;
- 19 (M) Morphine;
- (N) Oxycodone; 20
- (0) Oxymorphone; 21
- 22 (P) Oripavine;
- (Q) Thebaine; and 23
- 24 (R) Dihydroetorphine;
- (2) Any salt, compound, derivative, or preparation thereof which is 25
- chemically equivalent to or identical with any of the substances referred 26
- to in subdivision (1) of this subdivision, except that these substances 27
- shall not include the isoquinoline alkaloids of opium; 28
- 29 (3) Opium poppy and poppy straw;
- (4) Coca leaves and any salt, compound, derivative, or preparation 30
- 31 of coca leaves, and any salt, compound, derivative, or preparation

1 thereof which is chemically equivalent to or identical with any of these

- 2 substances, including cocaine or ecgonine and its salts, optical isomers,
- 3 and salts of optical isomers, except that the substances shall not
- 4 include decocainized coca leaves or extractions which do not contain
- 5 cocaine or ecgonine; and
- 6 (5) Concentrate of poppy straw, the crude extract of poppy straw in
- 7 either liquid, solid, or powder form which contains the phenanthrene
- 8 alkaloids of the opium poppy.
- 9 (b) Unless specifically excepted or unless in another schedule any
- 10 of the following opiates, including their isomers, esters, ethers, salts,
- 11 and salts of their isomers, esters, and ethers whenever the existence of
- 12 such isomers, esters, ethers, and salts is possible within the specific
- 13 chemical designation, dextrorphan excepted:
- 14 (1) Alphaprodine;
- 15 (2) Anileridine;
- 16 (3) Bezitramide;
- 17 (4) Diphenoxylate;
- 18 (5) Fentanyl;
- 19 (6) Isomethadone;
- 20 (7) Levomethorphan;
- 21 (8) Levorphanol;
- 22 (9) Metazocine;
- 23 (10) Methadone;
- 24 (11) Methadone-intermediate, 4-cyano-2-dimethylamino-4,4-diphenyl
- 25 butane;
- 26 (12) Moramide-intermediate, 2-methyl-3-morpholino-1,1-
- 27 diphenylpropane-carboxylic acid;
- 28 (13) Norfentanyl (N-phenyl-N-piperidin-4-yl) propionamide;
- 29 (14) Oliceridine;
- 30 (15) Pethidine or meperidine;
- 31 (16) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;

1 (17) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-

- 2 carboxylate;
- 3 (18) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-
- 4 carboxylic acid;
- 5 (19) Phenazocine;
- 6 (20) Piminodine;
- 7 (21) Racemethorphan;
- 8 (22) Racemorphan;
- 9 (23) Dihydrocodeine;
- 10 (24) Bulk Propoxyphene in nondosage forms;
- 11 (25) Sufentanil;
- 12 (26) Alfentanil;
- 13 (27) Levo-alphacetylmethadol which is also known as levo-alpha-
- 14 acetylmethadol, levomethadyl acetate, and LAAM;
- 15 (28) Carfentanil;
- 16 (29) Remifentanil;
- 17 (30) Tapentadol; and
- 18 (31) Thiafentanil.
- 19 (c) Any material, compound, mixture, or preparation which contains
- 20 any quantity of the following substances having a potential for abuse
- 21 associated with a stimulant effect on the central nervous system:
- 22 (1) Amphetamine, its salts, optical isomers, and salts of its
- 23 optical isomers;
- 24 (2) Phenmetrazine and its salts;
- 25 (3) Methamphetamine, its salts, isomers, and salts of its isomers;
- 26 (4) Methylphenidate; and
- 27 (5) Lisdexamfetamine, its salts, isomers, and salts of its isomers.
- 28 (d) Any material, compound, mixture, or preparation which contains
- 29 any quantity of the following substances having a potential for abuse
- 30 associated with a depressant effect on the central nervous system,
- 31 including their salts, isomers, and salts of isomers whenever the

1 existence of such salts, isomers, and salts of isomers is possible within

- 2 the specific chemical designations:
- 3 (1) Amobarbital;
- 4 (2) Secobarbital;
- 5 (3) Pentobarbital;
- 6 (4) Phencyclidine; and
- 7 (5) Glutethimide.
- 8 (e) Hallucinogenic substances known as:
- 9 (1) Nabilone. Another name for nabilone: (+/-)-trans-3-(1,1-
- dimethylheptyl)- 6,6a,7,8,10,10a-Hexahydro-1-hydroxy-6,6-dimethyl-9H-
- dibenzo(b,d)pyran-9-one; and
- 12 (2) Dronabinol in an oral solution in a drug product approved by the
- 13 federal Food and Drug Administration.
- 14 (f) Unless specifically excepted or unless listed in another
- 15 schedule, any material, compound, mixture, or preparation which contains
- 16 any quantity of the following substances:
- 17 (1) Immediate precursor to amphetamine and methamphetamine:
- 18 Phenylacetone. Trade and other names shall include, but are not limited
- 19 to: Phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl
- 20 ketone;
- 21 (2) Immediate precursors to phencyclidine, PCP:
- 22 (A) 1-phenylcyclohexylamine; or
- 23 (B) 1-piperidinocyclohexanecarbonitrile, PCC; or
- 24 (3) Immediate precursor to fentanyl; 4-anilino-N-phenethylpiperidine
- 25 (ANPP).
- 26 Schedule III
- 27 (a) Any material, compound, mixture, or preparation which contains
- 28 any quantity of the following substances having a potential for abuse
- 29 associated with a stimulant effect on the central nervous system,
- 30 including their salts, isomers, whether optical, position, or geometric,
- 31 and salts of such isomers whenever the existence of such salts, isomers,

1 and salts of isomers is possible within the specific chemical

- 2 designation:
- 3 (1) Benzphetamine;
- 4 (2) Chlorphentermine;
- 5 (3) Clortermine; and
- 6 (4) Phendimetrazine.
- 7 (b) Any material, compound, mixture, or preparation which contains
- 8 any quantity of the following substances having a potential for abuse
- 9 associated with a depressant effect on the central nervous system:
- 10 (1) Any substance which contains any quantity of a derivative of
- 11 barbituric acid or any salt of a derivative of barbituric acid, except
- 12 those substances which are specifically listed in other schedules of this
- 13 section;
- 14 (2) Aprobarbital;
- 15 (3) Butabarbital;
- 16 (4) Butalbital;
- 17 (5) Butethal;
- 18 (6) Butobarbital;
- 19 (7) Chlorhexadol;
- 20 (8) Embutramide;
- 21 (9) Lysergic acid;
- 22 (10) Lysergic acid amide;
- 23 (11) Methyprylon;
- 24 (12) Perampanel;
- 25 (13) Secbutabarbital;
- 26 (14) Sulfondiethylmethane;
- 27 (15) Sulfonethylmethane;
- 28 (16) Sulfonmethane;
- 29 (17) Nalorphine;
- 30 (18) Talbutal;
- 31 (19) Thiamylal;

- 1 (20) Thiopental;
- 2 (21) Vinbarbital;
- 3 (22) Any compound, mixture, or preparation containing amobarbital,
- 4 secobarbital, pentobarbital, or any salt thereof and one or more other
- 5 active medicinal ingredients which are not listed in any schedule;
- 6 (23) Any suppository dosage form containing amobarbital,
- 7 secobarbital, pentobarbital, or any salt of any of these drugs and
- 8 approved by the federal Food and Drug Administration for marketing only
- 9 as a suppository;
- 10 (24) Any drug product containing gamma-hydroxybutyric acid,
- 11 including its salts, isomers, and salts of isomers, for which an
- 12 application is approved under section 505 of the Federal Food, Drug, and
- 13 Cosmetic Act, 21 U.S.C. 355, as such section existed on January 1, 2014;
- 14 (25) Ketamine, its salts, isomers, and salts of isomers. Some other
- 15 names for ketamine: (+/-)-2-(2-chlorophenyl)-2-(methylamino)-
- 16 cyclohexanone; and
- 17 (26) Tiletamine and zolazepam or any salt thereof. Trade or other
- 18 names for a tiletamine-zolazepam combination product shall include, but
- 19 are not limited to: telazol. Trade or other names for tiletamine shall
- 20 include, but are not limited to: 2-(ethylamino)-2-(2-thienyl)-
- 21 cyclohexanone. Trade or other names for zolazepam shall include, but are
- 22 not limited to: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-
- 23 trimethylpyrazolo-(3,4-e) (1,4)-diazepin-7(1H)-one, and flupyrazapon.
- 24 (c) Unless specifically excepted or unless listed in another
- 25 schedule:
- 26 (1) Any material, compound, mixture, or preparation containing
- 27 limited quantities of any of the following narcotic drugs, or any salts
- 28 calculated as the free anhydrous base or alkaloid, in limited quantities
- 29 as set forth below:
- 30 (A) Not more than one and eight-tenths grams of codeine per one
- 31 hundred milliliters or not more than ninety milligrams per dosage unit,

1 with an equal or greater quantity of an isoquinoline alkaloid of opium;

- 2 (B) Not more than one and eight-tenths grams of codeine per one
- 3 hundred milliliters or not more than ninety milligrams per dosage unit,
- 4 with one or more active, nonnarcotic ingredients in recognized
- 5 therapeutic amounts;
- 6 (C) Not more than one and eight-tenths grams of dihydrocodeine per
- 7 one hundred milliliters or not more than ninety milligrams per dosage
- 8 unit, with one or more active, nonnarcotic ingredients in recognized
- 9 therapeutic amounts;
- 10 (D) Not more than three hundred milligrams of ethylmorphine per one
- 11 hundred milliliters or not more than fifteen milligrams per dosage unit,
- 12 with one or more active, nonnarcotic ingredients in recognized
- 13 therapeutic amounts;
- 14 (E) Not more than five hundred milligrams of opium per one hundred
- 15 milliliters or per one hundred grams, or not more than twenty-five
- 16 milligrams per dosage unit, with one or more active, nonnarcotic
- ingredients in recognized therapeutic amounts; and
- 18 (F) Not more than fifty milligrams of morphine per one hundred
- 19 milliliters or per one hundred grams with one or more active, nonnarcotic
- 20 ingredients in recognized therapeutic amounts; and
- 21 (2) Any material, compound, mixture, or preparation containing any
- 22 of the following narcotic drug or its salts, as set forth below:
- 23 (A) Buprenorphine.
- 24 (d) Unless contained on the list of exempt anabolic steroids of the
- 25 Drug Enforcement Administration of the United States Department of
- 26 Justice as the list existed on January 31, 2021, any anabolic steroid,
- 27 which shall include any material, compound, mixture, or preparation
- 28 containing any quantity of the following substances, including its salts,
- 29 isomers, and salts of isomers whenever the existence of such salts of
- 30 isomers is possible within the specific chemical designation:
- 31 (1) 3-beta, 17-dihydroxy-5a-androstane;

```
LB22
                                                                             LB22
2023
                                                                             2023
  1
           (2) 3-alpha, 17-beta-dihydroxy-5a-androstane;
  2
           (3) 5-alpha-androstan-3,17-dione;
  3
           (4)
                 1-androstenediol (3-beta,17-beta-dihydroxy-5-alpha-androst-1-
  4
      ene);
                1-androstenediol (3-alpha, 17-beta-dihydroxy-5-alpha-androst-1-
  5
           (5)
  6
      ene);
  7
           (6) 4-androstenediol (3-beta, 17-beta-dihydroxy-androst-5-ene);
  8
           (7) 5-androstenediol (3-beta, 17-beta-dihydroxy-androst-5-ene);
  9
           (8) 1-androstenedione ([5-alpha]-androst-1-en-3,17-dione);
 10
           (9) 4-androstenedione (androst-4-en-3,17-dione);
 11
           (10) 5-androstenedione (androst-5-en-3,17-dione);
 12
                                             (7-alpha, 17-alpha-dimethyl-17-beta-
           (11)
                        Bolasterone
 13
      hydroxyandrost-4-en-3-one);
 14
           (12) Boldenone (17-beta-hydroxyandrost-1, 4-diene-3-one);
           (13) Boldione (androsta-1, 4-diene-3, 17-3-one);
 15
           (14) Calusterone (7-beta, 17-alpha-dimethyl-17-beta-hydroxyandrost-4-
 16
 17
      en-3-one);
 18
           (15) Clostebol (4-chloro-17-beta-hydroxyandrost-4-en-3-one);
                 Dehydrochloromethyltestosterone (4-chloro-17-beta-hydroxy-17-
 19
 20
      alpha-methyl-androst-1,4-dien-3-one);
 21
                  Desoxymethyltestosterone
                                             (17-alpha-methyl-5-alpha-androst-2-
 22
      en-17-beta-ol) (a.k.a. 'madol');
 23
           (18) Delta-1-Dihydrotestosterone (a.k.a. '1-testosterone')(17-beta-
 24
      hydroxy-5-alpha-androst-1-en-3-one);
 25
           (19) 4-Dihydrotestosterone (17-beta-hydroxy-androstan-3-one);
 26
           (20)
                     Drostanolone
                                        (17-beta-hydroxy-2-alpha-methyl-5-alpha-
 27
      androstan-3-one);
 28
           (21) Ethylestrenol (17-alpha-ethyl-17-beta-hydroxyestr-4-ene);
 29
           (22)
                   Fluoxymesterone
                                      (9-fluoro-17-alpha-methyl-11-beta, 17-beta-
 30
      dihydroxyandrost-4-en-3-one);
                  Formebulone
                                 (formebolone);
 31
           (23)
                                                   (2-formyl-17-alpha-methyl-11-
```

```
2023
                                                                             2023
 1
      alpha, 17-beta-dihydroxyandrost-1, 4-dien-3-one);
 2
           (24)
                 Furazabol
                             (17-alpha-methyl-17-beta-hydroxyandrostano[2,3-c]-
  3
      furazan);
 4
           (25) 13-beta-ethyl-17-beta-hydroxygon-4-en-3-one;
 5
           (26) 4-hydroxytestosterone (4,17-beta-dihydroxy-androst-4-en-3-one);
  6
           (27) 4-hydroxy-19-nortestosterone (4,17-beta-dihydroxy-estr-4-en-3-
  7
      one);
                  Mestanolone
                                 (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-
 8
           (28)
 9
     one);
 10
           (29)
                  Mesterolone
                                 (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-
 11
     one);
 12
           (30)
                  Methandienone
                                    (17-alpha-methyl-17-beta-hydroxyandrost-1,4-
 13
      dien-3-one);
           (31) Methandriol (17-alpha-methyl-3-beta, 17-beta-dihydroxyandrost-5-
 14
 15
      ene);
           (32)
                 Methasterone (2-alpha, 17-alpha-dimethyl-5-alpha-androstan-17-
 16
 17
      beta-ol-3-one);
                 Methenolone (1-methyl-17-beta-hydroxy-5-alpha-androst-1-en-3-
 18
           (33)
 19
     one);
           (34) 17-alpha-methyl-3-beta,17-beta-dihydroxy-5a-androstane;
 20
 21
           (35) 17-alpha-methyl-3-alpha, 17-beta-dihydroxy-5a-androstane;
 22
           (36) 17-alpha-methyl-3-beta, 17-beta-dihydroxyandrost-4-ene;
 23
           (37)
                    17-alpha-methyl-4-hydroxynandrolone
                                                             (17-alpha-methyl-4-
 24
      hydroxy-17-beta-hydroxyestr-4-en-3-one);
 25
           (38) Methyldienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9(10)-
 26
      dien-3-one);
 27
           (39) Methyltrienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9,11-
      trien-3-one);
 28
 29
                 Methyltestosterone (17-alpha-methyl-17-beta-hydroxyandrost-4-
 30
      en-3-one);
 31
           (41)
                 Mibolerone
                               (7-alpha, 17-alpha-dimethyl-17-beta-hydroxyestr-4-
```

```
2023
                                                                             2023
 1
      en-3-one);
  2
                     17-alpha-methyl-delta-1-dihydrotestosterone
           (42)
                                                                        (17-beta-
  3
      hydroxy-17-alpha-methyl-5-alpha-androst-1-en-3-one) (a.k.a.
                                                                       '17-alpha-
 4
     methyl-1-testosterone');
 5
           (43) Nandrolone (17-beta-hydroxyestr-4-en-3-one);
  6
           (44) 19-nor-4-androstenediol (3-beta, 17-beta-dihydroxyestr-4-ene);
 7
           (45) 19-nor-4-androstenediol (3-alpha, 17-beta-dihydroxyestr-4-ene);
 8
           (46) 19-nor-5-androstenediol (3-beta, 17-beta-dihydroxyestr-5-ene);
 9
           (47) 19-nor-5-androstenediol (3-alpha, 17-beta-dihydroxyestr-5-ene);
 10
           (48)
                 19-nor-4,9(10)-androstadienedione
                                                     (estra-4,9(10)-diene-3,17-
 11
      dione);
 12
           (49) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
 13
           (50) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
 14
           (51) Norbolethone (13-beta, 17-alpha-diethyl-17-beta-hydroxygon-4-
 15
      en-3-one);
           (52) Norclostebol (4-chloro-17-beta-hydroxyestr-4-en-3-one);
 16
 17
           (53)
                  Norethandrolone
                                     (17-alpha-ethyl-17-beta-hydroxyestr-4-en-3-
 18
      one);
                 Normethandrolone (17-alpha-methyl-17-beta-hydroxyestr-4-en-3-
 19
          (54)
 20
      one);
 21
                 Oxandrolone (17-alpha-methyl-17-beta-hydroxy-2-oxa-[5-alpha]-
 22
      androstan-3-one);
 23
                                  (17-alpha-methyl-4, 17-beta-dihydroxyandrost-4-
           (56)
                  0xymesterone
 24
      en-3-one);
 25
           (57)
                   Oxymetholone
                                    (17-alpha-methyl-2-hydroxymethylene-17-beta-
 26
      hydroxy-[5-alpha]-androstan-3-one);
 27
           (58)
                     Prostanozol
                                        (17-beta-hydroxy-5-alpha-androstano[3,2-
      c]pyrazole);
 28
 29
           (59)
                    Stanozolol
                                     (17-alpha-methyl-17-beta-hydroxy-[5-alpha]-
 30
      androst-2-eno[3,2-c]-pyrazole);
 31
           (60) Stenbolone (17-beta-hydroxy-2-methyl-[5-alpha]-androst-1-en-3-
```

```
2023
                                                                             2023
 1
      one);
  2
           (61) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-
  3
      oic acid lactone);
           (62) Testosterone (17-beta-hydroxyandrost-4-en-3-one);
  4
  5
                                                       17-alpha-diethyl-17-beta-
           (63)
                  Tetrahydrogestrinone
                                          (13-beta,
  6
      hydroxygon-4,9,11-trien-3-one);
 7
           (64) Trenbolone (17-beta-hydroxyestr-4,9,11-trien-3-one);
           (65) [3,2-c]-furazan-5 alpha-androstane-17 beta-ol;
 8
 9
           (66) [3,2-c]pyrazole-androst-4-en-17 beta-ol;
 10
           (67) 17 alpha-methyl-androst-ene-3,17 beta-diol;
           (68) 17 alpha-methyl-androsta-1, 4-diene-3, 17 beta-diol;
11
 12
           (69) 17 alpha-methyl-androstan-3-hydroxyimine-17 beta-ol;
           (70) 17 beta-hydroxy-androstano[2,3-d]isoxazole;
 13
           (71) 17 beta-hydroxy-androstano[3,2-c]isoxazole;
14
           (72) 18a-homo-3-hydroxy-estra-2,5(10)-dien-17-one;
 15
           (73) 2 alpha, 3 alpha-epithio-17 alpha-methyl-5 alpha-androstan-17
 16
 17
      beta-ol;
 18
           (74) 4-chloro-17 alpha-methyl-17 beta-hydroxy-androst-4-en-3-one;
                 4-chloro-17 alpha-methyl-17 beta-hydroxy-androst-4-en-3,11-
 19
           (75)
 20
      dione;
           (76) 4-chloro-17 alpha-methyl-androst-4-ene-3 beta,17 beta-diol;
 21
 22
           (77) 4-chloro-17 alpha-methyl-androsta-1,4, diene-3,17 beta-diol;
           (78) 4-hydroxy-androst-4-ene-3,17-dione;
 23
           (79) 5 alpha-Androstan-3,6,17-trione;
 24
 25
           (80) 6-bromo-androst-1, 4-diene-3, 17-dione;
           (81) 6-bromo-androstan-3,17-dione;
 26
           (82) 6 alpha-methyl-androst-4-ene-3,17-dione;
 27
 28
           (83) Delta 1-dihydrotestosterone;
           (84) Estra-4,9,11-triene-3,17-dione; and
 29
           (85) Any salt, ester, or ether of a drug or substance described or
 30
      listed in this subdivision if the salt, ester, or ether promotes muscle
 31
```

- 1 growth.
- 2 (e) Hallucinogenic substances known as:
- 3 (1) Dronabinol, synthetic, in sesame oil and encapsulated in a soft
- 4 gelatin capsule in a drug product approved by the federal Food and Drug
- 5 Administration. Some other names for dronabinol are (6aR-
- 6 trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo
- 7 (b,d)pyran-1-ol or (-)-delta-9-(trans)-tetrahydrocannabinol.
- 8 Schedule IV
- 9 (a) Any material, compound, mixture, or preparation which contains
- 10 any quantity of the following substances, including their salts, isomers,
- 11 and salts of isomers whenever the existence of such salts, isomers, and
- 12 salts of isomers is possible within the specific chemical designation:
- 13 (1) Barbital;
- 14 (2) Chloral betaine;
- 15 (3) Chloral hydrate;
- 16 (4) Chlordiazepoxide, but not including librax (chlordiazepoxide
- 17 hydrochloride and clindinium bromide) or menrium (chlordiazepoxide and
- 18 water soluble esterified estrogens);
- 19 (5) Clonazepam;
- 20 (6) Clorazepate;
- 21 (7) Diazepam;
- 22 (8) Ethchlorvynol;
- 23 (9) Ethinamate;
- 24 (10) Flurazepam;
- 25 (11) Mebutamate;
- 26 (12) Meprobamate;
- 27 (13) Methohexital;
- 28 (14) Methylphenobarbital;
- 29 (15) Oxazepam;
- 30 (16) Paraldehyde;
- 31 (17) Petrichloral;

LB22 2023			LB22 2023
1	(18)	Phenobarbital;	
2	(19)	Prazepam;	
3	(20)	Alprazolam;	
4	(21)	Bromazepam;	
5	(22)	Camazepam;	
6	(23)	Clobazam;	
7	(24)	Clotiazepam;	
8	(25)	Cloxazolam;	
9	(26)	Delorazepam;	
10	(27)	Estazolam;	
11	(28)	Ethyl loflazepate;	
12	(29)	Fludiazepam;	
13	(30)	Flunitrazepam;	
14	(31)	Halazepam;	
15	(32)	Haloxazolam;	
16	(33)	Ketazolam;	
17	(34)	Loprazolam;	
18	(35)	Lorazepam;	
19	(36)	Lormetazepam;	
20	(37)	Medazepam;	
21	(38)	Nimetazepam;	
22	(39)	Nitrazepam;	
23	(40)	Nordiazepam;	
24	(41)	Oxazolam;	
25	(42)	Pinazepam;	
26	(43)	Temazepam;	
27	(44)	Tetrazepam;	
28	(45)	Triazolam;	
29	(46)	Midazolam;	
30	(47)	Quazepam;	
31	(48)	Zolpidem;	

-47-

(6) SPA, ((-)-1-dimethylamino- 1,2-diphenylethane);

31

1 (7) Cathine. Another name for cathine is ((+)-norpseudoephedrine);

- 2 (8) Fencamfamin;
- 3 (9) Fenproporex;
- 4 (10) Mefenorex;
- 5 (11) Modafinil; and
- 6 (12) Sibutramine.
- 7 (d) Unless specifically excepted or unless listed in another
- 8 schedule, any material, compound, mixture, or preparation which contains
- 9 any quantity of the following narcotic drugs, or their salts or isomers
- 10 calculated as the free anhydrous base or alkaloid, in limited quantities
- 11 as set forth below:
- 12 (1) Propoxyphene in manufactured dosage forms;
- 13 (2) Not more than one milligram of difenoxin and not less than
- 14 twenty-five micrograms of atropine sulfate per dosage unit; and
- 15 (3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its
- 16 salts, optical and geometric isomers, and salts of these isomers to
- 17 include: Tramadol.
- 18 (e) Unless specifically excepted or unless listed in another
- 19 schedule, any material, compound, mixture, or preparation which contains
- 20 any quantity of the following substance, including its salts:
- 21 (1) Pentazocine; and
- 22 (2) Butorphanol (including its optical isomers).
- 23 (f) Any material, compound, mixture, or preparation which contains
- 24 any quantity of the following substances, including its salts, isomers,
- 25 and salts of such isomers, whenever the existence of such salts, isomers,
- 26 and salts of isomers is possible: Lorcaserin.
- 27 (q)(1) Unless specifically excepted or unless listed in another
- 28 schedule, any material, compound, mixture, or preparation which contains
- 29 any quantity of the following substance, including its salts, optical
- 30 isomers, and salts of such optical isomers: Ephedrine.
- 31 (2) The following drug products containing ephedrine, its salts,

optical isomers, and salts of such optical isomers, are excepted from 1 2 subdivision (g)(1) of Schedule IV if they (A) are stored behind a counter, in an area not accessible to customers, or in a locked case so 3 4 that a customer needs assistance from an employee to access the drug 5 product; (B) are sold by a person, eighteen years of age or older, in the course of his or her employment to a customer eighteen years of age or 6 older with the following restrictions: No customer shall be allowed to 7 purchase, receive, or otherwise acquire more than three and six-tenths 8 9 grams of ephedrine base during a twenty-four-hour period; no customer 10 shall purchase, receive, or otherwise acquire more than nine grams of ephedrine base during a thirty-day period; and the customer shall display 11 a valid driver's or operator's license, a Nebraska state identification 12 card, a military identification card, an alien registration card, or a 13 passport as proof of identification; (C) are labeled and marketed in a 14 manner consistent with the pertinent OTC Tentative Final or Final 15 16 Monograph; (D) are manufactured and distributed for legitimate medicinal use in a manner that reduces or eliminates the likelihood of abuse; and 17 (E) are not marketed, advertised, or represented in any manner for the 18 indication of stimulation, mental alertness, euphoria, ecstasy, a buzz or 19 high, heightened sexual performance, or increased muscle mass: 20

- 21 (i) Primatene Tablets; and
- 22 (ii) Bronkaid Dual Action Caplets.
- 23 Schedule V
- (a) Any compound, mixture, or preparation containing any of the following limited quantities of narcotic drugs or salts calculated as the free anhydrous base or alkaloid, which shall include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:
- 30 (1) Not more than two hundred milligrams of codeine per one hundred 31 milliliters or per one hundred grams;

1 (2) Not more than one hundred milligrams of dihydrocodeine per one

- 2 hundred milliliters or per one hundred grams;
- 3 (3) Not more than one hundred milligrams of ethylmorphine per one
- 4 hundred milliliters or per one hundred grams;
- 5 (4) Not more than two and five-tenths milligrams of diphenoxylate
- 6 and not less than twenty-five micrograms of atropine sulfate per dosage
- 7 unit;
- 8 (5) Not more than one hundred milligrams of opium per one hundred
- 9 milliliters or per one hundred grams; and
- 10 (6) Not more than five-tenths milligram of difenoxin and not less
- 11 than twenty-five micrograms of atropine sulfate per dosage unit.
- 12 (b) Unless specifically exempted or excluded or unless listed in
- 13 another schedule, any material, compound, mixture, or preparation which
- 14 contains any quantity of the following substances having a stimulant
- 15 effect on the central nervous system, including its salts, isomers, and
- 16 salts of isomers: Pyrovalerone.
- 17 (c) Unless specifically exempted or excluded or unless listed in
- 18 another schedule, any material, compound, mixture, or preparation which
- 19 contains any quantity of the following substances having a depressant
- 20 effect on the central nervous system, including its salts, isomers, and
- 21 salts of isomers:
- 22 (1) Ezogabine (N-(2-amino-4-(4-fluorobenzylamino)-phenyl)-carbamic
- 23 acid ethyl ester);
- 24 (2) Lacosamide ((R)-2-acetoamido-N-benzyl-3-methoxy-propionamide);
- 25 (3) Pregabalin ((S)-3-(aminomethyl)-5-methylhexanoic acid);
- 26 (4) Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]
- 27 butanamide) (also referred to as BRV; UCB-34714; Briviact), including its
- 28 salts;
- 29 (5) Cenobamate; and
- 30 (6) Lasmiditan.
- 31 Sec. 6. Section 28-416, Revised Statutes Cumulative Supplement,

- 1 2022, is amended to read:
- 2 28-416 (1) Except as authorized by the Uniform Controlled Substances
- 3 Act, it shall be unlawful for any person knowingly or intentionally: (a)
- 4 To manufacture, distribute, deliver, dispense, or possess with intent to
- 5 manufacture, distribute, deliver, or dispense a controlled substance; or
- 6 (b) to create, distribute, or possess with intent to distribute a
- 7 counterfeit controlled substance.
- 8 (2) Except as provided in subsections (4), (5), (7), (8), (9), and
- 9 (10) of this section, any person who violates subsection (1) of this
- 10 section with respect to: (a) A controlled substance classified in
- 11 Schedule I, II, or III of section 28-405 which is an exceptionally
- 12 hazardous drug shall be guilty of a Class II felony; (b) any other
- 13 controlled substance classified in Schedule I, II, or III of section
- 14 28-405 shall be guilty of a Class IIA felony; or (c) a controlled
- 15 substance classified in Schedule IV or V of section 28-405 shall be
- 16 guilty of a Class IIIA felony.
- 17 (3) A person knowingly or intentionally possessing a controlled
- 18 substance, except marijuana or any substance containing a quantifiable
- 19 amount of the substances, chemicals, or compounds described, defined, or
- 20 delineated in subdivision (c)(25) (c)(26) of Schedule I of section
- 21 28-405, unless such substance was obtained directly or pursuant to a
- 22 medical order issued by a practitioner authorized to prescribe while
- 23 acting in the course of his or her professional practice, or except as
- 24 otherwise authorized by the act, shall be guilty of a Class IV felony. A
- 25 person shall not be in violation of this subsection if section 28-472 or
- 26 28-1701 applies.
- 27 (4)(a) Except as authorized by the Uniform Controlled Substances
- 28 Act, any person eighteen years of age or older who knowingly or
- 29 intentionally manufactures, distributes, delivers, dispenses, or
- 30 possesses with intent to manufacture, distribute, deliver, or dispense a
- 31 controlled substance or a counterfeit controlled substance (i) to a

- 1 person under the age of eighteen years, (ii) in, on, or within one
- 2 thousand feet of the real property comprising a public or private
- 3 elementary, vocational, or secondary school, a community college, a
- 4 public or private college, junior college, or university, or a
- 5 playground, or (iii) within one hundred feet of a public or private youth
- 6 center, public swimming pool, or video arcade facility shall be punished
- 7 by the next higher penalty classification than the penalty prescribed in
- 8 subsection (2), (7), (8), (9), or (10) of this section, depending upon
- 9 the controlled substance involved, for the first violation and for a
- 10 second or subsequent violation shall be punished by the next higher
- 11 penalty classification than that prescribed for a first violation of this
- 12 subsection, but in no event shall such person be punished by a penalty
- 13 greater than a Class IB felony.
- 14 (b) For purposes of this subsection:
- 15 (i) Playground means any outdoor facility, including any parking lot
- 16 appurtenant to the facility, intended for recreation, open to the public,
- 17 and with any portion containing three or more apparatus intended for the
- 18 recreation of children, including sliding boards, swingsets, and
- 19 teeterboards;
- 20 (ii) Video arcade facility means any facility legally accessible to
- 21 persons under eighteen years of age, intended primarily for the use of
- 22 pinball and video machines for amusement, and containing a minimum of ten
- 23 pinball or video machines; and
- 24 (iii) Youth center means any recreational facility or gymnasium,
- 25 including any parking lot appurtenant to the facility or gymnasium,
- 26 intended primarily for use by persons under eighteen years of age which
- 27 regularly provides athletic, civic, or cultural activities.
- 28 (5)(a) Except as authorized by the Uniform Controlled Substances
- 29 Act, it shall be unlawful for any person eighteen years of age or older
- 30 to knowingly and intentionally employ, hire, use, cause, persuade, coax,
- 31 induce, entice, seduce, or coerce any person under the age of eighteen

- 1 years to manufacture, transport, distribute, carry, deliver, dispense,
- 2 prepare for delivery, offer for delivery, or possess with intent to do
- 3 the same a controlled substance or a counterfeit controlled substance.
- 4 (b) Except as authorized by the Uniform Controlled Substances Act,
- 5 it shall be unlawful for any person eighteen years of age or older to
- 6 knowingly and intentionally employ, hire, use, cause, persuade, coax,
- 7 induce, entice, seduce, or coerce any person under the age of eighteen
- 8 years to aid and abet any person in the manufacture, transportation,
- 9 distribution, carrying, delivery, dispensing, preparation for delivery,
- 10 offering for delivery, or possession with intent to do the same of a
- 11 controlled substance or a counterfeit controlled substance.
- 12 (c) Any person who violates subdivision (a) or (b) of this
- 13 subsection shall be punished by the next higher penalty classification
- than the penalty prescribed in subsection (2), (7), (8), (9), or (10) of
- 15 this section, depending upon the controlled substance involved, for the
- 16 first violation and for a second or subsequent violation shall be
- 17 punished by the next higher penalty classification than that prescribed
- 18 for a first violation of this subsection, but in no event shall such
- 19 person be punished by a penalty greater than a Class IB felony.
- 20 (6) It shall not be a defense to prosecution for violation of
- 21 subsection (4) or (5) of this section that the defendant did not know the
- 22 age of the person through whom the defendant violated such subsection.
- 23 (7) Any person who violates subsection (1) of this section with
- 24 respect to cocaine or any mixture or substance containing a detectable
- 25 amount of cocaine in a quantity of:
- 26 (a) One hundred forty grams or more shall be guilty of a Class IB
- 27 felony;
- 28 (b) At least twenty-eight grams but less than one hundred forty
- 29 grams shall be guilty of a Class IC felony; or
- 30 (c) At least ten grams but less than twenty-eight grams shall be
- 31 guilty of a Class ID felony.

1 (8) Any person who violates subsection (1) of this section with

- 2 respect to base cocaine (crack) or any mixture or substance containing a
- 3 detectable amount of base cocaine in a quantity of:
- 4 (a) One hundred forty grams or more shall be guilty of a Class IB
- 5 felony;
- 6 (b) At least twenty-eight grams but less than one hundred forty
- 7 grams shall be guilty of a Class IC felony; or
- 8 (c) At least ten grams but less than twenty-eight grams shall be
- 9 quilty of a Class ID felony.
- 10 (9) Any person who violates subsection (1) of this section with
- 11 respect to heroin or any mixture or substance containing a detectable
- 12 amount of heroin in a quantity of:
- (a) One hundred forty grams or more shall be guilty of a Class IB
- 14 felony;
- 15 (b) At least twenty-eight grams but less than one hundred forty
- 16 grams shall be guilty of a Class IC felony; or
- 17 (c) At least ten grams but less than twenty-eight grams shall be
- 18 quilty of a Class ID felony.
- 19 (10) Any person who violates subsection (1) of this section with
- 20 respect to amphetamine, its salts, optical isomers, and salts of its
- 21 isomers, or with respect to methamphetamine, its salts, optical isomers,
- 22 and salts of its isomers, in a quantity of:
- (a) One hundred forty grams or more shall be guilty of a Class IB
- 24 felony;
- 25 (b) At least twenty-eight grams but less than one hundred forty
- 26 grams shall be guilty of a Class IC felony; or
- 27 (c) At least ten grams but less than twenty-eight grams shall be
- 28 guilty of a Class ID felony.
- 29 (11) Any person knowingly or intentionally possessing marijuana
- 30 weighing more than one ounce but not more than one pound shall be guilty
- 31 of a Class III misdemeanor.

- 1 (12) Any person knowingly or intentionally possessing marijuana
- 2 weighing more than one pound shall be guilty of a Class IV felony.
- (11) (13) Except as provided in section 28-1701, any person
- 4 knowingly or intentionally possessing marijuana weighing one ounce or
- 5 less or any substance containing a quantifiable amount of the substances,
- 6 chemicals, or compounds described, defined, or delineated in subdivision
- 7 (c)(25) (c)(26) of Schedule I of section 28-405 shall:
- 8 (a) For the first offense, be guilty of an infraction, receive a
- 9 citation, be fined three hundred dollars, and be assigned to attend a
- 10 course as prescribed in section 29-433 if the judge determines that
- 11 attending such course is in the best interest of the individual
- 12 defendant;
- 13 (b) For the second offense, be guilty of a Class IV misdemeanor,
- 14 receive a citation, and be fined four hundred dollars and may be
- 15 imprisoned not to exceed five days; and
- 16 (c) For the third and all subsequent offenses, be guilty of a Class
- 17 IIIA misdemeanor, receive a citation, be fined five hundred dollars, and
- 18 be imprisoned not to exceed seven days.
- 19 (12) (14) Any person convicted of violating this section, if placed
- 20 on probation, shall, as a condition of probation, satisfactorily attend
- 21 and complete appropriate treatment and counseling on drug abuse provided
- 22 by a program authorized under the Nebraska Behavioral Health Services Act
- 23 or other licensed drug treatment facility.
- 24 (13) (15) Any person convicted of violating this section, if
- 25 sentenced to the Department of Correctional Services, shall attend
- 26 appropriate treatment and counseling on drug abuse.
- 27 (14) (16) Any person knowingly or intentionally possessing a firearm
- 28 while in violation of subsection (1) of this section shall be punished by
- 29 the next higher penalty classification than the penalty prescribed in
- 30 subsection (2), (7), (8), (9), or (10) of this section, but in no event
- 31 shall such person be punished by a penalty greater than a Class IB

- 1 felony.
- 2 (15) (17) A person knowingly or intentionally in possession of money
- 3 used or intended to be used to facilitate a violation of subsection (1)
- 4 of this section shall be guilty of a Class IV felony.
- 5 (16) (18) In addition to the existing penalties available for a
- 6 violation of subsection (1) of this section, including any criminal
- 7 attempt or conspiracy to violate subsection (1) of this section, a
- 8 sentencing court may order that any money, securities, negotiable
- 9 instruments, firearms, conveyances, or electronic communication devices
- 10 as defined in section 28-833 or any equipment, components, peripherals,
- 11 software, hardware, or accessories related to electronic communication
- 12 devices be forfeited as a part of the sentence imposed if it finds by
- 13 clear and convincing evidence adduced at a separate hearing in the same
- 14 prosecution, following conviction for a violation of subsection (1) of
- 15 this section, and conducted pursuant to section 28-1601, that any or all
- 16 such property was derived from, used, or intended to be used to
- 17 facilitate a violation of subsection (1) of this section.
- 18 (17) (19) In addition to the penalties provided in this section:
- 19 (a) If the person convicted or adjudicated of violating this section
- 20 is eighteen years of age or younger and has one or more licenses or
- 21 permits issued under the Motor Vehicle Operator's License Act:
- 22 (i) For the first offense, the court may, as a part of the judgment
- 23 of conviction or adjudication, (A) impound any such licenses or permits
- 24 for thirty days and (B) require such person to attend a drug education
- 25 class;
- 26 (ii) For a second offense, the court may, as a part of the judgment
- 27 of conviction or adjudication, (A) impound any such licenses or permits
- 28 for ninety days and (B) require such person to complete no fewer than
- 29 twenty and no more than forty hours of community service and to attend a
- 30 drug education class; and
- 31 (iii) For a third or subsequent offense, the court may, as a part of

- 1 the judgment of conviction or adjudication, (A) impound any such licenses
- 2 or permits for twelve months and (B) require such person to complete no
- 3 fewer than sixty hours of community service, to attend a drug education
- 4 class, and to submit to a drug assessment by a licensed alcohol and drug
- 5 counselor; and
- 6 (b) If the person convicted or adjudicated of violating this section
- 7 is eighteen years of age or younger and does not have a permit or license
- 8 issued under the Motor Vehicle Operator's License Act:
- 9 (i) For the first offense, the court may, as part of the judgment of
- 10 conviction or adjudication, (A) prohibit such person from obtaining any
- 11 permit or any license pursuant to the act for which such person would
- 12 otherwise be eligible until thirty days after the date of such order and
- 13 (B) require such person to attend a drug education class;
- 14 (ii) For a second offense, the court may, as part of the judgment of
- 15 conviction or adjudication, (A) prohibit such person from obtaining any
- 16 permit or any license pursuant to the act for which such person would
- 17 otherwise be eligible until ninety days after the date of such order and
- 18 (B) require such person to complete no fewer than twenty hours and no
- 19 more than forty hours of community service and to attend a drug education
- 20 class; and
- 21 (iii) For a third or subsequent offense, the court may, as part of
- 22 the judgment of conviction or adjudication, (A) prohibit such person from
- 23 obtaining any permit or any license pursuant to the act for which such
- 24 person would otherwise be eligible until twelve months after the date of
- 25 such order and (B) require such person to complete no fewer than sixty
- 26 hours of community service, to attend a drug education class, and to
- 27 submit to a drug assessment by a licensed alcohol and drug counselor.
- A copy of an abstract of the court's conviction or adjudication
- 29 shall be transmitted to the Director of Motor Vehicles pursuant to
- 30 sections 60-497.01 to 60-497.04 if a license or permit is impounded or a
- 31 juvenile is prohibited from obtaining a license or permit under this

- 1 subsection.
- 2 (18) It shall not be an offense for a person to use or possess
- 3 marijuana.
- 4 Sec. 7. Section 28-417, Reissue Revised Statutes of Nebraska, is
- 5 amended to read:
- 6 28-417 (1) It shall be unlawful for any person:
- 7 (a) To omit, remove, alter, or obliterate a symbol required by the
- 8 federal Controlled Substances Act, 21 U.S.C. 801 et seq., as the act
- 9 existed on September 1, 2001, or required by the laws of this state;
- 10 (b) To alter, deface, or remove any label affixed to a package of
- 11 narcotic drugs;
- 12 (c) To refuse or fail to make, keep, or furnish any record,
- 13 notification, order form, statement, invoice, or information required
- 14 under the Uniform Controlled Substances Act;
- 15 (d) To refuse any entry into any premises for inspection authorized
- 16 by the act;
- 17 (e) To keep or maintain any store, shop, warehouse, dwelling house,
- 18 building, vehicle, boat, aircraft, or place whatever which such person
- 19 knows or should know is resorted to by persons using controlled
- 20 substances in violation of the Uniform Controlled Substances Act for the
- 21 purpose of using such substances or which is used for the keeping or
- 22 selling of the same in violation of the act;
- 23 (f) To whom or for whose use any controlled substance has been
- 24 prescribed, sold, or dispensed by a practitioner or the owner of any
- 25 animal for which any such substance has been prescribed, sold, or
- 26 dispensed by a veterinarian to possess it in a container other than which
- 27 it was delivered to him or her by the practitioner; or
- 28 (g) To be under the influence of any controlled substance, other
- 29 than marijuana, for a purpose other than the treatment of a sickness or
- 30 injury as prescribed or administered by a practitioner. In a prosecution
- 31 under this subdivision, it shall not be necessary for the state to prove

- 1 that the accused was under the influence of any specific controlled
- 2 substance, but it shall be sufficient for a conviction under this
- 3 subdivision for the state to prove that the accused was under the
- 4 influence of some controlled substance by proving that the accused did
- 5 manifest physical and physiological symptoms or reactions caused by the
- 6 use of any controlled substance.
- 7 (2) Any person who violates this section shall be guilty of a Class
- 8 III misdemeanor.
- 9 Sec. 8. Section 28-419, Reissue Revised Statutes of Nebraska, is
- 10 amended to read:
- 11 28-419 (1) No person shall breathe, inhale, or drink any compound,
- 12 liquid, or chemical containing acetate, acetone, benzene, butyl alcohol,
- 13 cyclohexanone, ethyl acetate, ethyl alcohol, ethylene dichloride,
- 14 ethylene trichloride, hexane, isopropanol, isopropyl alcohol, methyl
- 15 alcohol, methyl cellosolve acetate, methyl ethyl ketone, methyl isobutyl
- 16 ketone, pentachlorophenol, petroleum ether, toluene, toluol,
- 17 trichloroathane, trichloroethylene, or any other substance for the
- 18 purpose of inducing a condition of intoxication, stupefaction,
- 19 depression, giddiness, paralysis, inebriation, excitement, or irrational
- 20 behavior, or in any manner changing, distorting, or disturbing the
- 21 auditory, visual, mental, or nervous processes. For the purposes of
- 22 sections 28-419 to 28-424, any such condition so induced shall be deemed
- 23 an intoxicated condition.
- 24 (2) This section does not apply to the use of marijuana.
- 25 Sec. 9. Section 28-439, Reissue Revised Statutes of Nebraska, is
- 26 amended to read:
- 27 28-439 (1) As used in sections 28-101, 28-431, and 28-439 to
- 28 28-444, unless the context otherwise requires, drug paraphernalia shall
- 29 mean all equipment, products, and materials of any kind which are used,
- 30 intended for use, or designed for use, in manufacturing, injecting,
- 31 ingesting, inhaling, or otherwise introducing into the human body a

LB22 LB22 2023

2023

controlled substance in violation of sections 28-101, 28-431, and 28-439 1

- 2 to 28-444 or the Uniform Controlled Substances Act. It shall include, but
- 3 not be limited to, the following:
- 4 (a) (1) Diluents and adulterants, such as quinine hydrochloride,
- mannitol, mannite, dextrose, and lactose, used, intended for use, or 5
- 6 designed for use in cutting controlled substances;
- 7 (2) Separation gins and sifters used, intended for use, or designed
- for use in removing twigs and seeds from, or in otherwise cleaning or 8
- 9 refining, marijuana;
- 10 (b) (3) Hypodermic syringes, needles, and other objects used,
- intended for use, and designed for use in parenterally injecting 11
- controlled substances into the human body; and 12
- 13 (c) (4) Objects used, intended for use, or designed for use in
- inhaling, or otherwise introducing marijuana, cocaine, 14 ingesting,
- hashish, or hashish oil into the human body. , which shall include but 15
- not be limited to the following: 16
- (2) Items used or intended for use in the consumption, manufacture, 17
- cultivation, or processing of marijuana shall not be considered drug 18
- paraphernalia. 19
- (a) Metal, wooden, acrylic, glass, stone, plastic, or ceramic pipes 20
- with or without screens, permanent screens, hashish heads, or punctured 21
- 22 metal bowls;
- 23 (b) Water pipes;
- 24 (c) Carburetion tubes and devices;
- 25 (d) Smoking and carburetion masks;
- (e) Roach clips, meaning objects used to hold burning material, such 26
- as a marijuana cigarette, which has become too small or too short to be 27
- held in the hand; 28
- (f) Miniature cocaine spoons, and cocaine vials; 29
- (g) Chamber pipes; 30
- (h) Carburetor pipes; 31

- 1 (i) Electric pipes;
- 2 (j) Air-driven pipes;
- 3 (k) Chillums;
- 4 (1) Bongs; and
- 5 (m) Ice pipes or chillers.
- 6 Sec. 10. Section 28-1354, Revised Statutes Cumulative Supplement,
- 7 2022, is amended to read:
- 8 28-1354 For purposes of the Public Protection Act:
- 9 (1) Enterprise means any individual, sole proprietorship,
- 10 partnership, corporation, trust, association, or any legal entity, union,
- 11 or group of individuals associated in fact although not a legal entity,
- 12 and shall include illicit as well as licit enterprises as well as other
- 13 entities;
- 14 (2) Pattern of racketeering activity means a cumulative loss for one
- 15 or more victims or gains for the enterprise of not less than one thousand
- 16 five hundred dollars resulting from at least two acts of racketeering
- 17 activity, one of which occurred after August 30, 2009, and the last of
- 18 which occurred within ten years, excluding any period of imprisonment,
- 19 after the commission of a prior act of racketeering activity;
- 20 (3) Until January 1, 2017, person means any individual or entity, as
- 21 defined in section 21-2014, holding or capable of holding a legal,
- 22 equitable, or beneficial interest in property. Beginning January 1, 2017,
- 23 person means any individual or entity, as defined in section 21-214,
- 24 holding or capable of holding a legal, equitable, or beneficial interest
- 25 in property;
- 26 (4) Prosecutor includes the Attorney General of the State of
- 27 Nebraska, the deputy attorney general, assistant attorneys general, a
- 28 county attorney, a deputy county attorney, or any person so designated by
- 29 the Attorney General, a county attorney, or a court of the state to carry
- 30 out the powers conferred by the act;
- 31 (5) Racketeering activity includes the commission of, criminal

- 1 attempt to commit, conspiracy to commit, aiding and abetting in the
- 2 commission of, aiding in the consummation of, acting as an accessory to
- 3 the commission of, or the solicitation, coercion, or intimidation of
- 4 another to commit or aid in the commission of any of the following:
- 5 (a) Offenses against the person which include: Murder in the first
- 6 degree under section 28-303; murder in the second degree under section
- 7 28-304; manslaughter under section 28-305; assault in the first degree
- 8 under section 28-308; assault in the second degree under section 28-309;
- 9 assault in the third degree under section 28-310; terroristic threats
- 10 under section 28-311.01; kidnapping under section 28-313; false
- 11 imprisonment in the first degree under section 28-314; false imprisonment
- 12 in the second degree under section 28-315; sexual assault in the first
- degree under section 28-319; and robbery under section 28-324;
- 14 (b) Offenses relating to controlled substances which include: To
- 15 unlawfully manufacture, distribute, deliver, dispense, or possess with
- 16 intent to manufacture, distribute, deliver, or dispense a controlled
- 17 substance under subsection (1) of section 28-416; possession of marijuana
- 18 weighing more than one pound under subsection (12) of section 28-416;
- 19 possession of money used or intended to be used to facilitate a violation
- 20 of subsection (1) of section 28-416 prohibited under subsection (15) (17)
- 21 of section 28-416; any violation of section 28-418; to unlawfully
- 22 manufacture, distribute, deliver, or possess with intent to distribute or
- 23 deliver an imitation controlled substance under section 28-445;
- 24 possession of anhydrous ammonia with the intent to manufacture
- 25 methamphetamine under section 28-451; and possession of ephedrine,
- 26 pseudoephedrine, or phenylpropanolamine with the intent to manufacture
- 27 methamphetamine under section 28-452;
- 28 (c) Offenses against property which include: Arson in the first
- 29 degree under section 28-502; arson in the second degree under section
- 30 28-503; arson in the third degree under section 28-504; burglary under
- 31 section 28-507; theft by unlawful taking or disposition under section

5

31

1 28-511; theft by shoplifting under section 28-511.01; theft by deception

2 under section 28-512; theft by extortion under section 28-513; theft of

3 services under section 28-515; theft by receiving stolen property under

4 section 28-517; criminal mischief under section 28-519; and unlawfully

depriving or obtaining property or services using a computer under

6 section 28-1344;

(d) Offenses involving fraud which include: Burning to defraud an 7 insurer under section 28-505; forgery in the first degree under section 8 9 28-602; forgery in the second degree under section 28-603; criminal possession of a forged instrument under section 28-604; criminal 10 possession of written instrument forgery devices under section 28-605; 11 criminal impersonation under section 28-638; identity theft under section 12 13 28-639; identity fraud under section 28-640; false statement or book entry under section 28-612; tampering with a publicly exhibited contest 14 under section 28-614; issuing a false financial statement for purposes of 15 16 obtaining a financial transaction device under section 17 unauthorized use of a financial transaction device under section 28-620; criminal possession of a financial transaction device under section 18 28-621; unlawful circulation of a financial transaction device in the 19 first degree under section 28-622; unlawful circulation of a financial 20 transaction device in the second degree under section 28-623; criminal 21 possession of a blank financial transaction device under section 28-624; 22 criminal sale of a blank financial transaction device under section 23 24 28-625; criminal possession of a financial transaction forgery device 25 under section 28-626; unlawful manufacture of a financial transaction device under section 28-627; laundering of sales forms under section 26 28-628; unlawful acquisition of sales form processing services under 27 28 section 28-629; unlawful factoring of a financial transaction device under section 28-630; and fraudulent insurance acts under section 28-631; 29 (e) Offenses involving governmental operations which include: Abuse 30

of public records under section 28-911; perjury or subornation of perjury

- 1 under section 28-915; bribery under section 28-917; bribery of a witness
- 2 under section 28-918; tampering with a witness or informant or jury
- 3 tampering under section 28-919; bribery of a juror under section 28-920;
- 4 assault on an officer, an emergency responder, a state correctional
- 5 employee, a Department of Health and Human Services employee, or a health
- 6 care professional in the first degree under section 28-929; assault on an
- 7 officer, an emergency responder, a state correctional employee, a
- 8 Department of Health and Human Services employee, or a health care
- 9 professional in the second degree under section 28-930; assault on an
- 10 officer, an emergency responder, a state correctional employee, a
- 11 Department of Health and Human Services employee, or a health care
- 12 professional in the third degree under section 28-931; and assault on an
- 13 officer, an emergency responder, a state correctional employee, a
- 14 Department of Health and Human Services employee, or a health care
- professional using a motor vehicle under section 28-931.01;
- 16 (f) Offenses involving gambling which include: Promoting gambling in
- 17 the first degree under section 28-1102; possession of gambling records
- under section 28-1105; gambling debt collection under section 28-1105.01;
- 19 and possession of a gambling device under section 28-1107;
- 20 (g) Offenses relating to firearms, weapons, and explosives which
- 21 include: Carrying a concealed weapon under section 28-1202;
- 22 transportation or possession of machine guns, short rifles, or short
- 23 shotguns under section 28-1203; unlawful possession of a handgun under
- 24 section 28-1204; unlawful transfer of a firearm to a juvenile under
- 25 section 28-1204.01; possession of a firearm by a prohibited juvenile
- 26 offender under section 28-1204.05; using a deadly weapon to commit a
- 27 felony or possession of a deadly weapon during the commission of a felony
- 28 under section 28-1205; possession of a deadly weapon by a prohibited
- 29 person under section 28-1206; possession of a defaced firearm under
- 30 section 28-1207; defacing a firearm under section 28-1208; unlawful
- 31 discharge of a firearm under section 28-1212.02; possession, receipt,

1 retention, or disposition of a stolen firearm under section 28-1212.03;

LB22

2023

- 2 unlawful possession of explosive materials in the first degree under
- 3 section 28-1215; unlawful possession of explosive materials in the second
- 4 degree under section 28-1216; unlawful sale of explosives under section
- 5 28-1217; use of explosives without a permit under section 28-1218;
- 6 obtaining an explosives permit through false representations under
- 7 section 28-1219; possession of a destructive device under section
- 8 28-1220; threatening the use of explosives or placing a false bomb under
- 9 section 28-1221; using explosives to commit a felony under section
- 10 28-1222; using explosives to damage or destroy property under section
- 11 28-1223; and using explosives to kill or injure any person under section
- 12 28-1224;
- (h) Any violation of the Securities Act of Nebraska pursuant to
- 14 section 8-1117;
- 15 (i) Any violation of the Nebraska Revenue Act of 1967 pursuant to
- 16 section 77-2713;
- 17 (j) Offenses relating to public health and morals which include:
- 18 Prostitution under section 28-801; pandering under section 28-802;
- 19 keeping a place of prostitution under section 28-804; labor trafficking,
- 20 sex trafficking, labor trafficking of a minor, or sex trafficking of a
- 21 minor under section 28-831; a violation of section 28-1005; and any act
- 22 relating to the visual depiction of sexually explicit conduct prohibited
- 23 in the Child Pornography Prevention Act; and
- 24 (k) A violation of the Computer Crimes Act;
- 25 (6) State means the State of Nebraska or any political subdivision
- 26 or any department, agency, or instrumentality thereof; and
- 27 (7) Unlawful debt means a debt of at least one thousand five hundred
- 28 dollars:
- 29 (a) Incurred or contracted in gambling activity which was in
- 30 violation of federal law or the law of the state or which is
- 31 unenforceable under state or federal law in whole or in part as to

- 1 principal or interest because of the laws relating to usury; or
- 2 (b) Which was incurred in connection with the business of gambling
- 3 in violation of federal law or the law of the state or the business of
- 4 lending money or a thing of value at a rate usurious under state law if
- 5 the usurious rate is at least twice the enforceable rate.
- 6 Sec. 11. Section 28-1701, Revised Statutes Cumulative Supplement,
- 7 2022, is amended to read:
- 8 28-1701 (1) A person shall not be arrested or prosecuted for an
- 9 eligible alcohol or drug offense if such person witnessed or was the
- 10 victim of a sexual assault and such person:
- 11 (a) Either:
- 12 (i) In good faith, reported such sexual assault to law enforcement;
- 13 or
- 14 (ii) Requested emergency medical assistance for the victim of the
- 15 sexual assault; and
- 16 (b) Evidence supporting the arrest or prosecution of the eligible
- 17 alcohol or drug offense was obtained or discovered as a result of such
- 18 person reporting such sexual assault to law enforcement or requesting
- 19 emergency medical assistance.
- 20 (2) A person shall not be arrested or prosecuted for an eligible
- 21 alcohol or drug offense if:
- 22 (a) Evidence supporting the arrest or prosecution of the person for
- 23 the offense was obtained or discovered as a result of the investigation
- 24 or prosecution of a sexual assault; and
- (b) Such person cooperates with law enforcement in the investigation
- 26 or prosecution of the sexual assault.
- 27 (3) For purposes of this section:
- 28 (a) Eligible alcohol or drug offense means:
- (i) A violation of subsection (3) or (11) (13) of section 28-416 or
- 30 of section 28-441;
- 31 (ii) A violation of section 53-180.02 committed by a person older

1 than eighteen years of age and under the age of twenty-one years, as

- 2 described in subdivision (4)(a) of section 53-180.05;
- 3 (iii) A violation of a city or village ordinance similar to
- 4 subdivision (3)(a)(i) or (ii) of this section; or
- 5 (iv) Attempt, conspiracy, solicitation, being an accessory to,
- 6 aiding and abetting, aiding the consummation of, or compounding a felony
- 7 with any of the offenses in subdivision (3)(a)(i), (ii), or (iii) of this
- 8 section as the underlying offense; and
- 9 (b) Sexual assault means:
- 10 (i) A violation of section 28-316.01, 28-319, 28-319.01, 28-320,
- 11 28-320.01, 28-320.02, 28-322.01, 28-322.02, 28-322.03, 28-322.04,
- 12 28-322.05, 28-703, or 28-1463.03, sex trafficking or sex trafficking of a
- 13 minor under section 28-831, or subdivision (1)(c) or (g) of section
- 14 28-386 or subdivision (1)(d), (e), or (f) of section 28-707; or
- 15 (ii) Attempt, conspiracy, solicitation, being an accessory to,
- 16 aiding and abetting, aiding the consummation of, or compounding a felony
- 17 with any of the offenses listed in subdivision (3)(b)(i) of this section
- 18 as the underlying offense.
- 19 Sec. 12. Section 77-4301, Reissue Revised Statutes of Nebraska, is
- 20 amended to read:
- 21 77-4301 For purposes of sections 77-4301 to 77-4316:
- 22 (1) Controlled substance means shall mean any drug or substance,
- 23 including an imitation controlled substance, that is held, possessed,
- 24 transported, transferred, sold, or offered to be sold in violation of
- 25 Nebraska law. Controlled substance does shall not include marijuana;
- 26 (2) Dealer means shall mean a person who, in violation of Nebraska
- 27 law, manufactures, produces, ships, transports, or imports into Nebraska
- 28 or in any manner acquires or possesses six or more ounces of marijuana,
- 29 seven or more grams of any controlled substance which is sold by weight,
- 30 or ten or more dosage units of any controlled substance which is not sold
- 31 by weight;

1 (3) Imitation controlled substance <u>has</u> shall have the meaning as

- 2 provided in section 28-401; and
- 3 (4) Marijuana <u>has</u> shall have the meaning as provided in section
- 4 28-401.
- 5 Sec. 13. Section 77-4302, Reissue Revised Statutes of Nebraska, is
- 6 amended to read:
- 7 77-4302 No dealer may possess marijuana or controlled substances
- 8 upon which a tax is imposed by section 77-4303 unless the tax has been
- 9 paid on the marijuana or controlled substance as evidenced by an official
- 10 stamp, label, or other indicium.
- 11 Sec. 14. Section 77-4303, Reissue Revised Statutes of Nebraska, is
- 12 amended to read:
- 13 77-4303 (1) A tax is hereby imposed on marijuana and controlled
- 14 substances at the following rates:
- 15 (a) On each ounce of marijuana or each portion of an ounce, one
- 16 hundred dollars;
- 17 <u>(a) (b)</u> On each gram or portion of a gram of a controlled substance
- 18 that is customarily sold by weight or volume, one hundred fifty dollars;
- 19 or
- 20 <u>(b)</u> (c) On each fifty dosage units or portion thereof of a
- 21 controlled substance that is not customarily sold by weight, five hundred
- 22 dollars.
- 23 (2) For purposes of calculating the tax under this section,
- 24 marijuana or any controlled substance that is customarily sold by weight
- 25 or volume shall be measured by the weight of the substance in the
- 26 dealer's possession. The weight shall be the actual weight, if known, or
- 27 the estimated weight as determined by the Nebraska State Patrol or other
- 28 law enforcement agency. Such determination shall be presumed to be the
- 29 weight of such marijuana or controlled substances for purposes of
- 30 sections 77-4301 to 77-4316.
- 31 (3) The tax shall not be imposed upon a person registered or

1 otherwise lawfully in possession of marijuana or a controlled substance

- 2 pursuant to Chapter 28, article 4.
- 3 Sec. 15. Section 77-4304, Reissue Revised Statutes of Nebraska, is
- 4 amended to read:
- 5 77-4304 (1) Subject to the rules and regulations of the Tax
- 6 Commissioner, official stamps, labels, or other indicia to be affixed to
- 7 all marijuana and controlled substances shall be purchased from the
- 8 Department of Revenue. The purchaser shall pay one hundred percent of
- 9 face value for each official stamp, label, or other indicium purchased
- 10 and shall not be required to give his or her name, address, social
- 11 security number, or other identifying information.
- 12 (2) The Tax Commissioner shall adopt a uniform system of providing,
- 13 affixing, and displaying an official stamp, label, or other indicium for
- 14 marijuana and controlled substances on which a tax is imposed. Official
- 15 stamps, labels, or other indicia shall expire six months from the date of
- 16 issuance.
- 17 Sec. 16. Section 77-4305, Reissue Revised Statutes of Nebraska, is
- 18 amended to read:
- 19 77-4305 The tax imposed upon marijuana and controlled substances by
- 20 section 77-4303 shall be due and payable immediately upon acquisition or
- 21 possession of marijuana and controlled substances in this state by a
- 22 dealer.
- 23 Sec. 17. Section 77-4306, Reissue Revised Statutes of Nebraska, is
- 24 amended to read:
- 25 77-4306 If a dealer acquires or ships, transports, or imports into
- 26 this state marijuana or a controlled substance and if the official stamp,
- 27 label, or indicium evidencing the payment of the tax has not already been
- 28 affixed, the dealer shall have it permanently affixed on the marijuana or
- 29 controlled substance immediately upon acquisition or possession of the
- 30 marijuana or controlled substance. Each official stamp, label, or other
- 31 indicium may be used only once.

1 Sec. 18. Section 77-4309, Reissue Revised Statutes of Nebraska, is

- 2 amended to read:
- 3 77-4309 Any dealer violating sections 77-4301 to 77-4316 shall be
- 4 subject to a penalty of one hundred percent of the tax in addition to the
- 5 tax imposed by section 77-4303. The penalty shall be collected as part of
- 6 the tax.
- 7 A dealer distributing or possessing marijuana or a controlled
- 8 substance without affixing the official stamp, label, or other indicium
- 9 shall be guilty of a Class IV felony. Notwithstanding any other provision
- 10 of the criminal laws of this state, an indictment may be found and filed
- 11 or an information or complaint filed upon any criminal offense specified
- in this section in the proper court within six years after the commission
- 13 of such offense.
- 14 Sec. 19. Section 77-4310.01, Reissue Revised Statutes of Nebraska,
- is amended to read:
- 16 77-4310.01 Proceeds of the tax imposed by section 77-4303 shall be
- 17 remitted to the State Treasurer for credit as follows:
- 18 (1) Five percent of such proceeds shall be credited to the Marijuana
- 19 and Controlled Substances Tax Administration Cash Fund; and
- 20 (2) Of the remaining proceeds:
- 21 (a) Fifty percent shall be remitted to the respective counties from
- 22 which the proceeds originated for credit to the County Drug Law
- 23 Enforcement and Education Fund of each such county. Money remitted to a
- 24 county pursuant to this subdivision shall be remitted to the county
- 25 treasurer of such county for credit to such fund. For purposes of this
- 26 subdivision, county from which the proceeds originated shall mean: (i) If
- 27 the proceeds result from seizure under the Uniform State Tax Lien
- 28 Registration and Enforcement Act of property located in a county other
- 29 than the county in which the dealer resides, the county in which the
- 30 seizure was made; and (ii) in all other cases, the county in which the
- 31 dealer resides; and

1 (b) All remaining funds, including those which did not originate in

- 2 a county, shall be credited to the Nebraska State Patrol Drug Control and
- 3 Education Cash Fund.
- 4 Sec. 20. Section 77-4310.03, Reissue Revised Statutes of Nebraska,
- 5 is amended to read:
- 6 77-4310.03 There is hereby created the Marijuana and Controlled
- 7 Substances Tax Administration Cash Fund. Money in the fund shall be used
- 8 by the Tax Commissioner for the purposes of administering, collecting,
- 9 and enforcing the tax imposed by section 77-4303, except that transfers
- 10 may be made from the fund to the General Fund at the direction of the
- 11 Legislature. Any money in the Marijuana and Controlled Substances Tax
- 12 Administration Cash Fund available for investment shall be invested by
- 13 the state investment officer pursuant to the Nebraska Capital Expansion
- 14 Act and the Nebraska State Funds Investment Act.
- 15 Sec. 21. Original sections 2-505, 2-506, 2-509, 28-417, 28-419,
- 16 28-439, 77-4301, 77-4302, 77-4303, 77-4304, 77-4305, 77-4306, 77-4309,
- 17 77-4310.01, and 77-4310.03, Reissue Revised Statutes of Nebraska, and
- 18 sections 28-401, 28-405, 28-416, 28-1354, and 28-1701, Revised Statutes
- 19 Cumulative Supplement, 2022, are repealed.
- 20 Sec. 22. The following sections are outright repealed: Sections
- 21 2-5701, 28-463, 28-464, 28-465, 28-466, 28-467, 28-468, and 28-469,
- 22 Reissue Revised Statutes of Nebraska.